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1. ABSTRACT 
Background. Infections caused by Pseudomonas aeruginosa are the main cause of 
morbidity and mortality in Cystic Fibrosis (CF) patients and occur via primary colonisation 
of the airway followed by the accumulation of pathoadaptive mutations in the bacterial 
genome which increase fitness in the lung environment and result in chronicization. A 
better understanding of i) the evolutionary dynamics occurring during chronic airway 
infections in CF patients and ii) the genetic adaptation of strains to the CF lung 
environment, might give further clues for preventive measures or novel therapies to 
control CF infections in the future. In this work, we obtained genomic sequences of 40 P. 
aeruginosa isolates from a single CF patient collected over an eight-year period (2007-
2014) and analysed the population in terms of clonality of the isolates, phylogenetic 
relationships, and presence of polymorphisms and variants between the strains. 
Population structure and microevolution. In silico Multilocus Sequence Typing 
(MLST) analysis revealed a characteristic single clonal population dominated by a 
previously characterized sequence type (ST390) and a small number of new, closely related 
ST variants (ST1863, ST1864, ST1923). EBURST analysis of the sequence types revealed 
that all members of this population belong to the same clonal lineage and likely evolved 
from a single ancestral colonizing strain. Furthermore, the phylogenetic analysis based on 
SNPs also divided the population into two subpopulations derived from the evolution of 
the first infecting strain. 
The annotation of SNPs allowed us to identify mutations with moderate or high impact. 
Genes with high impact variants encoded respiratory nitrate reductase subunit 
gamma nail, polyprotein signal peptidase lspA, the ABC transporter-binding protein aaltP, 
the copper resistance protein A precursor pcoAin, and four hypothetical proteins.  
The evolution of strains in the CF airway is characterized by the loss of many virulence 
traits, including motility and protease secretion, along with the acquisition of multidrug 
resistance. Functional phenotypic assays of the collection, including motility and secretion 
of proteases, showed a decrease over time in the persistent isolates. We also determined 
the antibiotic susceptibility profile of the collection; while early isolates were found to be 
susceptible to almost all these antibiotics, resistant phenotypes dramatically increased over 
time in the population. 
Functional studies on specific strains. To identify additional functional variations 
related to pathoadaptive mutations occurring in the course of chronic infection in CF, we 
then selected three isolates for further characterization: one early CF isolate (TNCF_23 
isolated in 2007); one clonal late CF isolate (TNCF_175 isolated in 2014); one clinical 
isolate (VrPa97) from a non-CF patient belonging to the same sequence type (ST390) as 
the former isolates. With this approach, we aimed to identify additional phenotypic and 
functional variations between isolates with a very homogeneous genomic background, in 
an attempt to find out new pathoadaptive mutations occurring in the course of chronic 
infection in CF.  
Specifically, the following traits were investigated: killing of C. elegans and G. mellonella 
(in vivo virulence); immunomodulatory properties (IL-8 ELISA assay); competitive growth 
in Artificial Sputum Medium (ASM); functionality of Type Six Secretion System (T6SS). 
Despite their close genetic relatedness, considerable variations were observed between the 
three isolates, among which the late isolate TNCF_175 showed several alterations 
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putatively resulting from the adaptation process to the CF lung. TNCF_175 presented a 
mutation in tssK3, part of H3-T6SS; this mutation (C958T) was therefore introduced in 
the reference strains PAO1 and PA14, and mutated strains were subsequently 
complemented; killing rate on C. elegans and growth rate in ASM in mutant and 
complemented strains were evaluated. 
Conclusions. A rare feature of this strain collection is the consistent number of clonal 
isolates obtained from a single patient over a rather long period of 8 eight years, thus 
providing a model to look at microevolutionary trends within a highly homogenous 
bacterial population, and avoiding potential biases due to the host genetic background and 
clinical history. In spite of the close genomic relatedness of all isolates, a surprisingly high 
diversity was observed for the majority of tested phenotypes. Investigating the competitive 
ability of early versus late strains we propose a role for T6SS in the adaptation process to 
the CF lung environment. Our data suggest that once persistence has been established, a 
strain no longer requires its T6SS, allowing loss of function mutations to occur. 
Conversely, acute and early CF strains still carry a number of virulence factors, including 
T6SS that potentially provide an advantage in outcompeting other microorganisms in the 
initial stage of CF infection. 
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2. INTRODUCTION 
 
2.1. Pathogenesis of Cystic fibrosis 
Cystic fibrosis is the most common autosomal lethal genetic disease among the caucasian 
population, and it affects approximately one child out of 3000 [1]. The disease is 
characterized by high levels of epithelial chloride, pancreatic insufficiency, recurring lung 
infections and bronchiectasis, leading to death from respiratory failure [2].  
It is caused by a defect in the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) gene, which is located on the long arm of chromosome 7 and encodes a 1480-
amino acid membrane protein. In healthy individuals with non-impaired CFTR, the ion 
conductance across the membrane is well-regulated [3].  
CFTR belongs to the adenosine triphosphate (ATP)-binding cassette (ABC) transporter 
protein family. ABC transporters regulate the transmembrane transport of small 
molecules. CFTR consists of two homologous cytoplasmic nucleotide-binding domains 
(NBDs) and two membrane-spanning domains (MSDs) [4]. In normal conditions, CFTR 
allows chloride passage and regulates electrolytes exchange through the cellular 
membrane. Malfunctioning of CFTR protein causes a diminished Cl- secretion and 
increased Na+ absorption. 
Up until now, over 2000 mutations have been identified in the CFTR gene, but only 242 
were confirmed to cause CF [5]. The most common mutations in CF patients are divided 
into six classes, based on the mechanisms that cause aberrant synthesis or function of the 
protein (Fig.1) [5][6]:  
• Class I mutations: presence of a premature stop codon in mRNA or presence of 
major insertions and deletions that disrupt translation. The protein is not produced;  
• Class II mutations: abnormal protein processing or trafficking. The protein is not 
delivered to the membrane. ∆F508, the most common mutation present in 85-90% 
of white CF patients, belongs to this class [5]. The mutation consists of a three-base-
pair deletion leading to the loss of a phenylalanine residue. This deletion leads to 
the production of a misfolded CFTR that is not delivered to the cellular membrane 
and is degraded by the proteasome;  
• Class III mutations: abnormal protein regulation. The protein is not activated;  
• Class IV mutations: lead to changes in conductivity of the protein, causing abnormal 
chloride permeability;  
• Class V mutations: mutations present in promoter or splice regions. The protein is 
produced but at lower level;  
• Class VI mutations: CFTR is present at the cell surface but with a reduced stability, 
leading to an increased turnover of the protein. 
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Figure 1. Types of mutations in cystic fibrosis [6]. 
 
2.1.1. Impact of defective CFTR on the airway  
The apical surface of the airway epithelium is covered by a thin layer of fluid, the airway 
surface liquid (ASL). The volume of fluid, itspH, the presence of ions and nutrients are 
necessary to the airway’s antimicrobial activity and ciliary function [7]. ASL is composed of 
two layers: the upper mucus layer is more viscous and traps exogenous particles, the lower 
one is the periciliary layer (PCL), more fluid and allows cilia to beat to eliminate the mucus 
[7][8]. Furthermore, the presence of antimicrobial peptides produced by epithelium and 
immune responses like IgA and macrophages prevent microbial colonization [9].  
Sphingolipids are a class of lipids made of eighteen carbon amino-alcohol backbones which 
are synthesized in the ER. Modification of this basic structure gives rise to the large family 
of sphingolipids that play essential roles in membrane biology and provide metabolites 
that regulate cell function [10].  Defective CFTR or decreased CFTR expression increases 
sphingolipid synthesis, resulting in a significantly increased mass of sphingomyelin, 
sphingosine, and sphinganine, affecting membrane functionality [11][12][13]. 
Sphingomyelin is subsequently hydrolyzed to ceramide by the acidic, neutral and alkaline 
sphingomyelinase [14]. Ceramide molecules associate and bind to each other, resulting in 
the formation of ceramide-enriched membrane microdomains, which tend to cluster in 
macrodomains called ceramide-enriched membrane platforms [15][16][17]. Ceramide 
accumulation in bronchial, tracheal and intestinal epithelial cells, causes pulmonary 
inflammation, susceptibility to infection, peribronchial collagen deposition and cell death, 
triggering DNA release into the bronchial lumen along with the reduction of mucociliary 
clearance [14]. 
In CF lungs with a defective CFTR, the impaired Cl- ions movement creates an osmotic 
gradient, which in turn causes water hyper-reabsorption and retention into the cells and 
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leads to the formation of a thick and sticky ASL with reduced volume, causing an impaired 
mucociliary clearance and clogging the bronchial tubes [5][18].  
The abnormal viscous mucus adheres to the pulmonary epithelium and promotes further 
mucus retention, infection and inflammation, leading to tissue damage (Fig. 2). 
 
 
Figure 2. The ASL in CF [19].  (A) the normal airway: the ASL consists of a mucus layer containing large 
gel-forming mucins that trap inhaled particles for removal by mucociliary clearance. The CFTR transports 
chloride and bicarbonate into the airway. Sodium is absorbed via the epithelial sodium channel (ENaC), 
contributing to ASL hydration and mucociliary transport. SPLUNC1 is abundant within the ASL and 
regulates ASL volume by inhibiting ENaC. The ASL also contains antimicrobial factors, which play a crucial 
role in innate host defence. (B) the CF airway: defective chloride and bicarbonate transport by abnormal 
CFTR lead to a dehydrated and acidic ASL. SPLUNC1 fails to regulate ENaC, leading to sodium 
hyperabsorption and further ASL volume depletion. The acidic environment reduces antimicrobial function 
and increases mucus viscosity. These mechanisms result in the production of thick secretions and bacterial 
colonisation. In this dehydrated state, water preferentially moves out of the mucus layer, increasing its 
concentration. The PCL volume is initially preserved, but eventually, reaches a critical threshold at which 
water also exits the PCL. The mucus layer subsequently compresses the PCL, compromising ciliary activity 
and mucociliary clearance. 
 
There is also evidence that mutated CFTR can cause alterations of both innate and 
adaptive immune systems, leading to compromised bacterial eradication and dysregulated 
inflammation [5]. Impaired mucociliary clearance and compromised immune response 
predispose the patients to recurrent bronchopulmonary infections as mucus accumulation 
in the airways creates a suitable environment for microbial colonization, due to the 
presence of nutrients for microbial growth [18]. In CF patients morbidity and mortality are 
caused explicitly by chronic bacterial infection and inflammation of the pulmonary 
epithelium [20][21]. After an infection is established, its eradication with antibiotic 
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therapies may be very difficult. Lung infections can cause a progressive decline of the 
organ functions, respiratory insufficiency and death [18]. 
 
2.1.2 Microbiology of CF in the airway 
Impaired mucociliary clearance and compromised immune response predispose the 
patients to recurrent bronchopulmonary infections; mucus accumulation in the airways 
creates a suitable environment for microbial colonization, due to the presence of many 
nutrients for microbial growth [18]. In CF patients, morbidity and mortality are specifically 
caused by chronic bacterial infection and inflammation of the lungs [20][22].  
Different microbial communities coexist in the lungs of a CF patient, with the predominant 
bacterial species being Pseudomonas aeruginosa, Staphylococcus aureus and 
Haemophilus influenzae [23]. Staphylococcus aureus is the most prevalent pathogen 
during childhood, and its prevalence decreases over the years to about 40% in the 
adulthood [21].  Pseudomonas aeruginosa is the most common bacterium found in adult 
patients (prevalence of 60-70%) [23]. 
The source of the first P. aeruginosa strain infecting a CF patient is not entirely clear; 
although in several patients P. aeruginosa infections seem to originate from a nosocomial 
or social environment, in some cases, the source of the first acquisition appears to be 
environmental reservoirs [23][24]. 
Pseudomonas aeruginosa colonization of airways begins with recurrent acute infections 
eradicable with antibiotic therapies. Over the years the patient can be re-infected with 
different strains, but in about 25% of cases, the infection is due to strains belonging to the 
same genotype as the initial colonizer [23]. The re-colonization source can be a reservoir 
present in the environment or a different niche in the respiratory tract of the patient (e.g., 
the paranasal sinuses) [23]. Later, usually in patients’ mid-twenties, the intermittent acute 
infections turn into a chronic colonization, currently the factors driving this transition are 
still not well understood [23].  
Other pathogens, such as Stenotrophomonas maltophilia or Achromobacter xylosoxidans 
with a prevalence in adult patients of 11% and 7.5% respectively, whilst present are not 
associated with worse prognosis [25]. The prognosis dramatically worsens after 
Burkholderia cepacia complex (Bcc) colonization [26], however, the prevalence of 
Burkholderia species has decreased from 3.6% to 3.0% in the past 20 years [25] thanks to 
patient segregation [27]. Colonization and infection of the CF airway by fungi in the late 
stages of the disease also occur, given the exposure of the population to repeated broad-
spectrum antibiotic therapies [28]. 
 
2.2. Genomic studies on Pseudomonas aeruginosa 
The first available P. aeruginosa complete genome was the one of the reference strain 
PAO1 [29]. It is 6,3 Mbp long and contains 5570 open reading frames (ORFs). 
Pseudomonas aeruginosa has a single and supercoiled circular chromosome. PAO1 
genome shows a genetic complexity (several genes with unique function) rather than gene 
duplications. Pseudomonas aeruginosa has many paralogous groups (distinct gene 
families) suggesting that its genome has evolved through genetic expansion [29]. 
Moreover, 8,4% of P. aeruginosa PAO1 genes (521 ORFs) are predicted to be involved in 
regulation; these, in addition to its remarkable genetic complexity, enable P. aeruginosa to 
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adapt to different environmental conditions and hosts. The bacterium encodes numerous 
transporters putatively involved in antibiotic resistance, highlighting the significant 
problems associated with the control of P. aeruginosa infections. Several genomic islands 
were found in P. aeruginosa [30]. Genomic islands, differentially distributed among the  
strains [31], are horizontally acquired segments of DNA and frequently integrated adjacent 
to tRNA genes, with a G+C content distinct from that of the host core chromosome and 
containing components of mobile genetic elements [32]. Several genomic islands, also 
called pathogenicity islands, have been identified and characterized in P. aeruginosa. For 
example, a 49 kb island called P. aeruginosa genomic island 1 (PAGI-1) was found in a 
urinary tract infection strain and subsequently shown to be present in 85% of the clinical 
isolates tested [33]. The large genomic islands PAGI-2 and PAGI3 were identified by 
sequencing a hypervariable region of genomic plasticity and an environmental aquatic 
isolate [34]. Pseudomonas aeruginosa pathogenicity island-1 (PAPI-1) represents a large 
family of genomic islands derived from a pKLC102-like plasmid. pKLC102 is a 103.5 kb 
plasmid initially described in P. aeruginosa clone C strains that exists both as a plasmid or 
integrated into the chromosome; furthermore, it can excise from the chromosome at a rate 
of about 10% [35][36].  
In P. aeruginosa genomes, there is a conserved core component, defined as comprising all 
genes present in all sequenced genomes of P. aeruginosa, and an accessory component, 
that contains additional strain-specific regions formed by acquisition of clusters of genes 
by horizontal gene transfer in some strains and deletions of specific chromosomal 
segments in others [37]. Pseudomonas aeruginosa genome is organized as mosaics of 
conserved regions along with insertions containing blocks of strain-specific genes found in 
a small number of chromosomal locations called "regions of genomic plasticity" (RGP) 
[37]. 
Affordable Next Generation Sequencing (NGS) techniques that have allowed large-scale 
genomic studies to describe genetic adaptation that occurs in CF lung infections [38]. 
Several longitudinal studies have reported comparisons among clonally related isolates; 
these studies focused on mutations that have arisen from the early to the late stages of the 
infection [39][40][41][42][43][44]. These studies revealed mutations in different 
functional groups such as virulence, transport, iron acquisition, motility, DNA replication 
and repair, cell division, transcription and translation, metabolism, and antibiotic 
resistance. A longitudinal and extensive study on a collection of isolates belonging to a 
transmissible lineage (DK2), showed that sublineages could appear after the initial 
colonization and that they can evolve independently in patient’s lung by the accumulation 
of pathoadaptive mutations [40]. It has also been shown that hypermutator and non-
hypermutator strains can coexist in the CF lungs [45]. The same group demonstrated that 
the adaptation process of P. aeruginosa in cystic fibrosis infections shows a typical 
pattern: in a study of 474 longitudinal strains from 34 CF patients, 52 genes were found to 
be parallelly mutated in all the different lineages [46]. It has been observed in several 
patients that P. aeruginosa improves its ability to uptake iron from haemoglobin towards 
the late stages of infection [44]. At the earliest stages of infection, P. aeruginosa acquires 
mutations that affect global metabolic regulation, such as mutations in mucA and lasR, 
whereas, in the late phases, variations that occur are more specific and have smaller effects 
[23]. Mutations that lead to pathoadaptation appear to be different among diverse studies, 
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suggesting that P. aeruginosa follows distinct pathoadaptive trajectories [47], in fact, 
different mutations may lead to similar phenotypes [48].  
Despite the trend of P. aeruginosa to accumulate loss-of-function mutations throughout 
the progression of the infection, there are a number of transmissible strains (such as 
Liverpool Epidemic Strains (LES), Denmark Epidemic Strain (DK2) or Australian 
Epidemic Strains (AES)) that along with an increased CF lung fitness, show mutations that 
favour transmission [49][50][51]. These epidemic strains are concerning issues since they 
often display an MDR phenotype [52]. In a recent study, Lòpez-Causapé et al. [52] 
analysed a widespread clone (CC274) isolated in Australia and Spain, over an 18-year 
period. They report the coexistence of two divergent CC274 clonal lineages not split 
between the two countries; phylogenetic reconstructions and study of mutations leading to 
multidrug resistance showed an interpatient transmission of mutators. Mutations emerged 
in over 100 genes involved in antibiotic resistance during the evolution of CC274.  
 
2.3. Adaptation of Pseudomonas aeruginosa to the CF airway 
During the colonization of the CF airways, P. aeruginosa needs to change its nutritional 
and metabolic properties to survive in this new habitat. The CF airway exposes the 
bacterium to highly stressful conditions, due to the action of the host immune system, 
antibiotics therapies, competition with other microorganisms and osmotic stress [23]. All 
these factors influence P. aeruginosa microevolution and adaptation [23]. 
Young CF patients experience transient pulmonary infections, whereas the lungs become 
permanently colonized by P. aeruginosa in adulthood, and from this point onward the 
same bacterial lineage can persist in the airway for decades, and its eradication is hardly 
possible with currently available antibiotic therapies [53]. The characteristics of P. 
aeruginosa isolates present in late CF lung disease differ remarkably from isolates that 
first colonized the patient years before [23][18].  
Chronic respiratory infections by P. aeruginosa in cystic fibrosis are associated with 
genotypic and phenotypic changes [23]. The typical phenotypic changes are development 
of antibiotic resistance, decreased growth rate, reduced motility, changes in quorum 
sensing, and modified exopolysaccharides production [54]. 
Mutations are a significant source of genetic variation that helps bacteria to adapt and 
survive in a new habitat [39]. Smith et al. [39] sequenced the genome of two P. aeruginosa 
clonal isolates from a single CF patient, the first one isolated after six months from 
infection, while the second was a clonal descendant, isolated after 96 months. They found a 
high ratio of nonsynonymous to synonymous mutations, suggesting the occurrence of a 
positive selection process. About half of the mutations in the two isolates appeared to affect 
protein functions. In particular, mutations were found in virulence factors and regulators 
involved in O-antigen biosynthesis, type III secretion, motility, exotoxin A regulation, 
multidrug efflux, phenazine biosynthesis, quorum sensing, and iron acquisition. The 
isolate presented a mutation in mutS, which encodes a protein involved in the mismatch 
repair system, the mutation of which results in a hypermutable phenotype favouring 
bacterial adaptation [39]. 
Huse et al. studied the expression of a set of 24 genes in three different P. aeruginosa 
lineages and reported similar gene expression patterns. These results suggest the 
occurrence of convergent evolution in CF airways, i.e. closely related organisms develop 
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independently the same adaptive traits, in response to the surrounding environment [55]. 
Despite the convergence of phenotypic changes among clinical isolates, a high level of 
phenotypic diversity within a single patient and between multiple isolates from the same 
sputum sample has been reported [23][56]. In general, although most of P. aeruginosa 
infections have a clonal origin, chronic infections are characterized by an adaptive process 
leading to a marked diversification of the microbial clones into various morphotypes [57]. 
The adaptive process likely occurs independently in different bacteria of the population, 
originating subpopulations within the same host [9].   
 
2.4. Antibiotic resistance 
Antibiotic resistance is a hallmark of chronic-infection pathogens, especially in those 
associated with CF infections [58][59][60]. Bacteria acquire and use different resistance 
mechanisms to protect themselves in vivo such as efflux pumps, alterations in membrane 
permeability and enzymatic modification (i.e. β-lactamases) [61][62][63]. These resistance 
mechanisms can change during the course of the infection and after the exposure to 
antimicrobials [58].  
Compared to other pathogens, P. aeruginosa is difficult to eradicate because of its high 
intrinsic resistance to a wide range of antibiotics, including aminoglycosides, 
fluoroquinolones and β-lactams [64]. The most important mechanism underlying this 
ability is a low outer membrane permeability, which is 12–100 times lower than that of E. 
coli [65]. Pseudomonas aeruginosa shows a limited number of large channels of the major 
porin OprF and small other porins that mediate the passage of other molecules he size of 
antibiotics, such as OprD and OprB [64]. Different intrinsic mechanisms include rapid 
efflux [66][67] due to the expression of efflux pumps, like the systems MexAB–OprM and 
MexXY–OprM [64]. Horizontal gene transfer is a way to acquire antibiotic resistance [64]. 
For example, aminoglycoside modifying enzymes located on transposons can inactivate 
aminoglycosides by chemically altering the antimicrobial, lowering its affinity for the 30S 
ribosomal subunit [68].  
Spontaneous mutations are another mechanism by which P. aeruginosa acquires 
antimicrobial resistance [64]. Mutation rate can increase under particular conditions such 
as in the presence of DNA-damaging agents or during growth in biofilm. For example, the 
mutation frequency for Meropenem resistance dramatically increased when the culture 
was preincubated with sub-inhibitory concentrations of ciprofloxacin [69]. Furthermore, a 
>100-fold increased mutation rate for ciprofloxacin resistance was observed in biofilms 
rather than free-living cells [70], probably because of a downregulation of antioxidants 
leading to DNA damage [64]. Mutation frequency considerably increases in hypermutator 
strains with mutations in genes involved in the repair of DNA replication errors [71]. These 
strains quickly acquire resistance to different antibiotics. Examples of hypermutators are 
mutL and mutS, which are commonly found in CF patients [72]. 
Critical mutations are those leading to overexpression of efflux pumps, reduced uptake of 
antimicrobials, overproduction of β-lactamases and altered antibiotic targets [64]. For 
example, an critical mutational mechanism is the derepression of the efflux pumps 
MexAB–OprM and MexCD–OprJ caused by mutations in genes encoding mexR and nfxB, 
respectively [73].  
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Mutations in the specific porin OprD reduce the uptake of Imipenem [74], while mutations 
in either mexT or mexS reduce the expression of OprD and increase expression of the 
efflux pump MexEF–OprN leading to multiple antibiotic resistance [75].  
Overproduction of β-lactamases is related to mutations in AmpD, an effector of the ampC 
β-lactamase which directs the activity of the AmpR regulator [64]. Mutations in target 
enzymes can also result in resistance [76], e.g. mutations in gyrA and gyrB (gyrase) or 
parC and parE (topoisomerase IV). Environment and sub-inhibitory concentrations of 
antibiotics may lead to changes in gene expression in P. aeruginosa and allow the 
pathogen to cope with following exposures to lethal levels of antibiotics [64].  
A relevant adaptive mechanism in P. aeruginosa is the induction, caused by pre-exposure 
to β-lactam antibiotics, of a β-lactamase, encoded by the ampC gene, which leads to 
enzymatic inactivation of several β-lactams [64].  
A further resistance mechanism arising from the exposure to sub-inhibitory concentrations 
of antibiotics is the hyperexpression of genes coding for efflux pumps, such as 
aminoglycosides, which induce the MexXY efflux pump [77]. These regulatory changes in 
pump expression lead to a quicker antibiotic efflux, and P. aeruginosa becomes more 
resistant [77]. 
Recently, mutations were found in genes that had not been fully recognized as antibiotic-
related, like fusA1 and fusA2, both encoding elongation factor G (rpoC), which codes for 
the β-chain of a DNA-directed RNA polymerase [52]. 
 
2.5. Pseudomonas aeruginosa virulence factors 
Pseudomonas aeruginosa presents a multiplicity of regulatory systems allowing it to adapt 
to the environment [23]. Invasion, dissemination and extensive tissue damage 
predominate in acute infection. Initial infection may be favoured by the large genome of P. 
aeruginosa and its ability to sense and respond to a broad variety of environmental 
conditions, while late adaptation may in part result from the selection of clonal lineages 
containing mutations arising spontaneously [78]. During the transition from acute to 
chronic infection, the production of several factors of P. aeruginosa that exert destructive 
and immunostimulatory effects is reduced [53]. Virulence factors expression is under the 
control of complex regulatory circuits and multiple signalling systems. The bacterium 
produces a broad set of secreted virulence factors, under the control of the quorum sensing 
system. Accumulation of mutations in lasR commonly causes the loss of QS. [38]. 
Pseudomonas aeruginosa adapts by losing most immunogenic traits and acquiring other 
phenotypical characteristics (e.g., mucoid phenotype and biofilm formation) to escape host 
immune defences and avoid clearance (Fig. 3) [38]. 
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Figure 3. Pathoadaptive mutations in Pseudomonas aeruginosa. Genes encoding regulatory 
proteins are highlighted in red. Genes encoding sigma factors are highlighted in blue [38].  
 
The emergence of mucoid phenotype is a marker for the transition to chronic infection; 
mucoid P. aeruginosa is characterized by the overproduction of alginate, which is a 
polymer of D-mannuronic and L-glucuronic acid [57][38]. The shift from non-mucoid to 
mucoid phenotype is mainly due to loss-of-function mutations in mucA, which encodes an 
anti-σ factor that generally represses the expression of the algD operon carrying the genes 
coding for enzymes involved in alginate production [9][57]. Alginate promotes bacterial 
encapsulation, providing protection against antibiotics and host immune system, 
especially phagocytosis by macrophages and neutrophils [18]. However, mucoid P. 
aeruginosa triggers a vigorous antibody response, so the presence of mucoid phenotypes is 
associated with poor prognosis, with tissue damage and decreased lung function [18][57]. 
Furthermore, the conversion to a mucoid phenotype promotes biofilm formation, which is 
a key factor for the persistence of P. aeruginosa in the CF airways [18]. Biofilm is a 
community of microorganisms surrounded by an extracellular matrix that protects it. It 
has a distinct architecture with microcolonies surrounded by fluid-filled channels. Sessile 
lifestyle may confer antimicrobial resistance [79]. 
It has been shown that the zone where P. aeruginosa grows the most as biofilm is the area 
comprised between the trachea and terminal bronchioles [80]. Biofilms are an important 
issue in human disease management, because they lead to a dramatic increase in antibiotic 
tolerance [81][82]. 
Biofilm resistance is a result of the combination of different mechanisms, including 
diminished penetration of antimicrobials through the exopolysaccharide matrix, slow 
growth rate of bacteria within biofilms due to the reduced availability of nutrients and 
oxygen, accumulation of metabolic wastes, and quorum-sensing molecules 
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[83][84][85][86]. The decreased penetration of antibiotics and immunity molecules 
through the exopolysaccharide matrix represents an essential factor of P. aeruginosa 
persistence [18].  
Loss of motility is another feature that P. aeruginosa usually acquires during the switch to 
chronic phenotype. Swarming, swimming and twitching are the three different types of 
motility, the first two due to the presence of flagella and the last one to the presence of pili, 
which enable bacteria to adhere to the lung epithelium [57][87]. Several studies have 
shown that bacteria lacking flagella (e.g. due to mutations in fliC, rpoN, vfr, fleQ) are less 
phagocytized by macrophages and neutrophils, so their loss helps the bacterium evade host 
immune system and persist in the airway [18][57]. On the other hand, Hassett et al. [88] 
demonstrated the central role of alginate in bacterial protection against leukocyte killing 
and phagocytosis. Biofilm also appears to protect sessile communities from antibodies [89] 
and antibiotics [90]. 
The presence of pili is necessary for the initial colonization and the translocation of type III 
exotoxins [57]. The loss of pili could arise from mutations of pilB, which encodes an 
ATPase that enables pili extension and retraction, or from mutations in pilQ, required to 
extrude the pili from the outer membrane [91]. Mutations in rpoN lead to loss of both 
flagella and pili [92].  
Lipopolysaccharide (LPS) is a major virulence factor present in the outer membrane of 
Gram-negative bacteria. It consists of three regions: the hydrophobic lipid A region, a 
central core oligosaccharide region and a repeating polysaccharide portion, the O-antigen 
[93]. LPS triggers host immune response by binding to TLR2-4 and CD14; it causes 
pyrogenicity, platelet aggregation and cytokines production [9][94]. Chronic infections are 
often characterized by the modification of lipid A and the loss or reduced production of the 
O-antigen [9]. Lipid A from non-CF P. aeruginosa isolates is mainly penta-acylated 
(contains five acyl groups in the lipid bilayer of the outer membrane), while lipid A from 
CF isolates contains hexa- and hepta-acylated lipid A [95][96][97]. Loss of O-antigen 
results from the acquisition of mutations like frameshift deletions or integration of 
insertion elements in genes responsible for O-antigen production [98][92][99], or from 
deletion of all or large parts of the locus [100]. 
Pyocyanine is a blue phenazine that has a redox activity and can cause neutrophils death 
[101]. Siderophores are secondary metabolites used by bacteria to uptake iron from the 
environment [102]. Iron is essential for bacterial growth; it is indeed used in respiration 
processes and as a cofactor for enzymes [102]. Pseudomonas aeruginosa uses the yellow-
green fluorescent pigment pyoverdine (a siderophore) to seize iron [102]. 
Proteases are enzymes able to hydrolyse the peptide bonds of proteins; P. aeruginosa 
produces a broad set of proteases such as elastase B, alkaline protease, protease IV and 
PasP that play an important role in the pathogenic interaction between bacterium and host 
[103]. Loss of proteases production leads to a decrease in bacterial virulence [103]. 
The type III secretion system (T3SS) enables P. aeruginosa to deliver toxins into the 
cytoplasm of the host cells and is turned off during chronic infections, resulting in 
decreased cytotoxicity [104]. The toxins delivered by P. aeruginosa T3SS are ExoS and 
ExoT, which have an ADP-ribosyltransferase activity and decrease macrophage motility 
and phagocytosis; ExoY, which has an adenylate cyclase activity and affects cell 
morphology; ExoU, which is a cytotoxin and leads to epithelial cytotoxicity and lung injury 
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[105]. Patients infected with a strain expressing the T3SS show a higher rate of mortality 
and an increased incidence of bacteremia compared to the patients carrying P. aeruginosa 
defective of the T3SS [106]. 
Regulatory pathways associated with the switch from planktonic to sessile lifestyle were 
shown to be related to RetS and LadS signalling [107][108]. These two proteins modulate 
the activity of the GacS/GacA two-component system to control levels of sRNAs RsmY and 
RsmZ [109]. RetS inhibits GacS sensor [110], whereas LadS activates rsmY and rsmZ 
expression [109]. In the presence of high level of RsmY and RmsZ, the post-transcriptional 
regulator RsmA is removed from target transcripts to permit translation [109]. Moreover, 
RetS/LadS/Gac/Rsm cascade strictly regulates the production of virulence factors: a 
mutation in retS causes a downregulation of T3SS [107], suggesting that RsmA positively 
influences the expression of T3SS genes [111]. Conversely, the expression of the type VI 
secretion system (T6SS) was demonstrated to be negatively regulated by RsmA [111]. 
Therefore, P. aeruginosa appears to coordinate the expression of biofilm-related genes 
with genes coding for T6SS, both of which are related to chronic infection [109].  
Along with GacS/GacA signalling cascade, c-di-GMP is known to be an important second 
messenger for the switch to biofilm lifestyle [112], affecting either polysaccharide 
production and motility. For example, c-di-GMP showed to influence the production of Pel 
polysaccharides in P. aeruginosa (Fig. 4) [113][114][115]. By measuring intracellular c-di-
GMP levels in retS mutants, Moscoso et al. [109] (Fig. 4) found that they were much higher 
compared to wild-type P. aeruginosa strains; they also discovered that increased c-di-GMP 
levels in wild-type strains caused the switch from the expression of T3SS to T6SS, while 
decreased c-di-GMP levels caused the retS mutants switch from T6SS to T3SS. The control 
of the T3SS and the T6SS by c-di-GMP thus imitates regulation by RetS. The same group 
discovered how the c-di-GMP-dependent switching from T3SS to T6SS requires Gac/Rsm 
cascade. Therefore, in P. aeruginosa c-di-GMP and sRNAs coordinate together with the 
switch from T3SS to T6SS [109].  
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Figure 4. Regulatory networks that switch P. aeruginosa lifestyles. The retS and c-di-GMP 
signalling pathways act on the same targets to inversely control functions involved in motility versus bioﬁlm 
formation, or in acute versus chronic infection. The RetS/LadS signalling network converges on the post-
transcriptional regulator RsmA to inversely regulate the T3SS and the T6SS. The same regulation can be 
achieved by artiﬁcially modulating c-di-GMP levels upon overproduction of a diguanylate cyclase (DGC) or a 
phosphodiesterase (PDE). The dotted arrows indicate an unknown mechanism of action. Figure taken from 
Moscoso et al. [109]. 
 
2.5.1. Role of the T6SS in the progression of infection 
The type VI secretion system of Gram-negative bacteria is a nano-machine targeting 
competitive Gram-negative bacteria in different environments. T6SS injects toxins into 
cells, and the attacker is protected by cognate immunity proteins that are absent in target 
cells [116]. These toxins are essential for optimal fitness during host colonization where the 
pathogen could outcompete host-commensal bacteria [117] or get rid of competitors to 
establish a niche [118][119].  
Genes encoding T6SS components have been found in about 25% of Gram-negative 
bacteria [120], and P. aeruginosa has three T6SS: H1-T6SS, H2-T6SS and H3-T6SS. H1-
T6SS is involved in anti-prokaryotic activity [116]. In vitro, it secretes two categories of 
proteins: Hcp (hemolysin coregulated protein) and VgrG (Valine Glycine repeat protein) 
[121] (Fig. 5). Hcp is believed to be the counterpart of the gp19 protein forming the tail 
tube of the T4 bacteriophage [122]. VgrG proteins represent the spike at the top of the tube 
that is sharpened by a proline-alanine-alanine-arginine (PAAR) motif-containing proteins 
[123]. Tube and spike serve as puncturing tool that allows the injection of toxins into target 
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cells. The propulsion comes from at least 13 core components called Tss proteins that are 
associated with the membrane [124]. However, the assembly and the action of the 
machinery is still poorly understood [125]. 
 
 
Figure 5. Schematic representation of the structure and mechanism of the Type VI Secretion 
System [126]. (A) The extended machinery is assembled from cytoplasmic and membrane components. The 
membrane complex, contains TssJ, TssL, and TssM, represented in yellow, red and orange respectively. A 
putative baseplate-like structure, formed by TssAEFGK and rendered in brown, sits at the cytoplasmic face of 
the inner membrane. Upon VgrG, within the baseplate, an elongated tubular structure of Hcp hexamers 
(light blue) is built and extends into the cytoplasm, encompassed in a TssBC sheath (blue). (B) The second 
step corresponds to sheath contraction and propels the inner tube towards the target cell. PAAR and VgrG, 
represented in pink and purple triangles respectively, form the puncturing device responsible for membrane 
perforation prior to effector delivery. (C) Once effectors (grey stars) are delivered into the target cell, the 
contracted sheath is disassembled by ClpV (green hexamers). Abbreviations: IM, inner membrane; OM, 
outer membrane; PG, peptidoglycan. 
  
T6SS serves as a gun that injects at least seven effectors (Tse1-7) into other bacteria and 
produces anti-toxins (Tsi) that protect P.aeruginosa from the intrinsic effect of the toxins 
and the attack from neighbour cells [116].  
H1-T6SS was the first type six secretion system to be described, and it explicates 
antibacterial activity. Tse2, an effector injected via H1-T6SS, was found to cause 
quiescence in bacterial cells, and its immune cognate Tsi2 interacts with Tse2 in the 
cytoplasm to counteract its toxic effects [127]. Tse1 and Tse3 exert their activity in the 
periplasm of target bacterial cells by hydrolysing peptidoglycan [128]. Also, in this case, P. 
aeruginosa presents immunity proteins Tsi1 and Tsi3 to be protected against Tse1 and 
Tse3 toxicity [128]. In particular, it has been shown how Tsi3 blocks the active site of Tse3 
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stopping its enzymatic activity [129]. Tse4 and Tse5 (with their immunity cognate Tsi4 and 
Tsi5, respectively) is a toxic effector that acts at periplasmic level [130]. Tse6 was shown to 
degrade NAD(+) and NADP(+) causing bacteriostasis in the target cells [131]. All these 
toxins allow P. aeruginosa to outcompete other bacteria in the same niche [132]. 
Moreover H2- and H3-T6SS show antibacterial activity by injecting the phospholipase D 
enzymes PldA and PldB into other cells [133][134]. Pseudomonas aeruginosa H2-T6SS is 
responsible for the delivery of Tle5 toxin [133]. Tle5 activity can lead to membrane 
destabilization, blebbing and depolarization. This activity grants P. aeruginosa the 
capacity to use the enzyme against several different competitors (both eukaryotes and 
prokaryotes) [133].  
PldB is an H3-T6SS-dependent antibacterial effector [134]. PldB targets the periplasm of 
prokaryotic cells and also facilitates the intracellular invasion of host eukaryotic cells by 
activation of the PI3K/Akt pathway [134]. 
Regulators and growth conditions involved in H2- and H3-T6SS expression have been 
proposed, including quorum sensing and iron limitation [135][136]. Allsopp et al. [137] 
recently displayed H2- and H3-T6SS control by using transposon (Tn) mutagenesis and 
reporter fusions. They demonstrated that RsmA acts on most known T6SS genes, and 
showed that AmrZ is another global regulator of the T6SS. They also observed assembly of 
different T6SSs within a single cell; these results suggest that the three T6SSs are not 
mutually exclusive [137]. 
As described above, the T6SS is a contractile tail oriented towards the target cell and 
attached to the cell envelope by a membrane complex [138][139]. The membrane complex 
is a 1.7 MDa trans-envelope structure composed of three conserved subunits: the TssJ 
outer membrane lipoprotein and the TssL and TssM inner membrane proteins 
[140][141][142][143][125]. In several cases, the membrane complex is inserted and 
attached to the cell wall by additional proteins with peptidoglycan hydrolysis and 
peptidoglycan binding properties [141][144][145][146]. The contractile tail consists of an 
inner tube made of hexamers of the Hcp protein, stacked on each other [122][147], tipped 
by VgrG, and surrounded by a contractile sheath made of the TssBC proteins 
[122][147][148]. Polymerization of the tail tube structure is started on an assembly 
platform called the baseplate and is coordinated by the TssA protein [149][150][151]. Once 
the T6SS tail is built, the sheath contracts and propels the spike needle complex towards 
the target cell[152][152][153][154][155]. A recent in vivo study identified five components 
of the baseplate: TssE, TssF, TssG, TssK and VgrG [150]. T6SS baseplate subcomplexes 
were isolated in Serratia marcescens and uropathogenic Escherichia coli (UPEC), 
including the TssKFG or TssKFGE complexes [149][156]. Furthermore, TssK is a crucial 
baseplate subunit mediating contacts with the cytoplasmic domains of membrane complex 
components [151][157][158]. Therefore, TssK is an essential baseplate component 
connecting the membrane complex, baseplate and tail components. The TssK N-terminal 
domain attaches to the rest of the T6SS baseplate, and the C-terminal domain binds the 
membrane complex and has evolved to use the T6SS membrane complex as a receptor that 
attaches to the baseplate. The flexibility of the TssK C-terminal domain suggests that TssK 
may establish a flexible link to maintain the anchorage of the baseplate to the T6SS 
membrane complex [159]. 
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2.6. Aim of the thesis 
During my PhD, I have worked to advance our understanding on how P. aeruginosa 
adapts to the cystic fibrosis lung. By performing a longitudinal study of a 40-clonal isolate 
population, namely applying a series of genotypic and phenotypic analyses, I wanted to 
gain insights into how the population has evolved over time. Furthermore, by selecting a 
small number of isolates, I wanted to study in more detail pathoadaptive mutations that 
have occurred throughout the transition from the early/intermediate-infection strains to 
the chronic-infection strains. 
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3. POPULATION STRUCTURE AND MICROEVOLUTION 
In the past few years, whole-genome sequencing has significantly triggered the study of 
clonally related longitudinal isolates to define the genetic basis of the adaptation of P. 
aeruginosa to CF lung. In our study, 40 P. aeruginosa isolates isolated from a single cystic 
fibrosis patient between 2007 and 2014 were sequenced and the genomes were analysed. 
Furthermore, phenotypic traits of the population were determined. 
 
3.1. Materials and methods 
 
3.1.1. Strains 
We obtained 40 Pseudomonas aeruginosa isolates from a single cystic fibrosis male 
patient born in 1983 and followed up by the cystic fibrosis regional centre in Rovereto, 
Italy. His CFTR mutation profile is ∆F508/G542X. The strains were collected over an 
eight-year period (2007-2014) (Table 1a).  
 
Table 1a. Pseudomonas aeruginosa strains used in this work. Forty isolates came from a 
longitudinal sampling of sputum from a single cystic fibrosis patient. Along with this collection, an acute-
infection strain, VrPa97, was included in the analyses; the isolate derives from a wound swab collected in the 
intensive care unit at Verona Hospital, Italy. 
 
Isolate name Isolation date Sequence type Source  
TNCF_3 
13/04/2007 
390 CF sputum 
TNCF_4M 390 CF sputum 
TNCF_6 
29/05/2007 
390 CF sputum 
TNCF_7M 390 CF sputum  
TNCF_10 
26/07/2007 
390 CF sputum 
TNCF_10M 390 CF sputum 
TNCF_12 04/09/2007 390 CF sputum 
TNCF_13 
05/09/2007 
390 CF sputum 
TNCF_14 390 CF sputum 
TNCF_16 24/09/2007 1864 CF sputum 
TNCF_23 
17/10/2007 
390 CF sputum 
TNCF_23M 390 CF sputum 
TNCF_32 
23/11/2007 
390 CF sputum 
TNCF_32M 390 CF sputum 
TNCF_42 
31/01/2008 
390 CF sputum 
TNCF_42M 390 CF sputum 
TNCF_49M 05/09/2008 390 CF sputum 
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TNCF_68 02/08/2010 390 CF sputum 
TNCF_69 22/03/2010 1863 CF sputum 
TNCF_76 09/06/2010 390 CF sputum 
TNCF_85 08/11/2010 1864 CF sputum 
TNCF_88M 14/12/2010 1864 CF sputum 
TNCF_101 30/06/2011 1864 CF sputum 
TNCF_105 25/08/2011 390 CF sputum 
TNCF_106 16/09/2011 390 CF sputum 
TNCF_109 30/09/2011 390 CF sputum 
TNCF_130 19/07/2012 390 CF sputum 
TNCF_133 
14/09/2012 
390 CF sputum 
TNCF_133_1 1864 CF sputum 
TNCF_151 
05/04/2013 
390 CF sputum 
TNCF_151M 1864 CF sputum 
TNCF_154 29/04/2013 390 CF sputum 
TNCF_155 
06/05/2013 
390 CF sputum 
TNCF_155_1 1923 CF sputum 
TNCF_165 23/09/2013 1923 CF sputum 
TNCF_167 
03/10/2013 
390 CF sputum 
TNCF_167_1 390 CF sputum 
TNCF_174 24/04/2014 390 CF sputum 
TNCF_175 23/06/2014 390 CF sputum 
TNCF_176 11/08/2014 1923 CF sputum 
VrPa97 2007 390 Wound swab (acute 
infection) 
 
Table 1b. Control strains used in the phenotypic assays. 
 
 
Assay Positive control strain Negative control strain Supplier 
 Motility PAO1 Hannover PAO1 ∆pilA Craig Winstanley 
Protease secretion PA14 Ausubel / Craig Winstanley 
Hypermutability PAO1 ∆mutS PAO1 Hannover Craig Winstanley 
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3.1.2. Genome sequencing 
All strains were genome-sequenced using Illumina® MiSeq platform (Illumina®, San 
Diego, CA, USA). 
DNA was extracted from overnight cultures in Luria-Bertani (LB) broth (Sigma-Aldrich, 
Saint-Louis, MO, USA) with DNeasy Blood & Tissue Kit (Qiagen, Düsseldorf, Germany), 
quantified with Qubit dsDNA HS Assay kit (ThermoFisher Scientific, Waltham, MA, USA) 
and measured with Qubit 2.0 Fluorometer. 
Sample preparation was carried out with Nextera DNA Library Preparation Kit (Illumina), 
by which DNA was fragmented and tagged at the same time with sequencing adapters in a 
single step; this step is called “tagmentation” and is the first stage of a library preparation. 
Subsequently, the fragmented DNA was cleaned-up by removing the Nextera transposon 
that is likely to interfere with amplification. DNA was amplified and index adapters were 
added. After the amplification, the amplicons were purified by using AMPure XP Beads. 
After this stage, a quantification of DNA library templates was required: Qubit dsDNA HS 
Assay kit was the method of choice. Quality control check was performed with Agilent 
Technology 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) to check the size distribution 
of the library. Right before sequencing, a pooling of libraries in equal volumes was 
prepared. 
Genomes were sequenced on the Illumina MiSeq platform and assembled using SPAdes 
Genome Assembler version 3.1.0 [160]. 
Annotation of genomes was performed with Prokka automatic annotation tool v1.11 [161], 
and analysis of the core and accessory genomes was carried out using Roary with default 
settings [162]. SNPs were identified using Snippy (available at 
https://github.com/tseemann/snippy). This software infers polymorphisms at the 
nucleotide level by aligning the unassembled reads to a reference genome (in this work we 
used P. aeruginosa DK2). In addition, it calls the software SnpEff to annotate and predict 
the effect for each mutation [163], dividing them into low (e.g. synonym mutations), 
moderate (e.g. in-frame deletion/insertion) and high (e.g. stop gained). 
Genes with multiple SNPs were initially considered to be under non-neutral selection. This 
statement was further verified by the following procedure: i) the alignment of each 
homologous gene with reference sequence was exported in FASTA format; ii) the dN/dS 
ratio was determined using codeml as implemented in PAML package [164] and the 
likelihood of four different models (two neutral or nearly-neutral, M1a and M7 
respectively, and the two corresponding positive selection models M2a and M8) was 
determined; iii) the likelihood ratio test, using as null model the neutral one, was 
performed to determine which model better fitted the observed data. This procedure was 
implemented in a conservative way to detect non-neutral selection in highly similar 
sequences [165][166]. 
The occurrence and distribution of genomic islands in the population were inferred using 
IslandViewer4 [167]. Genbank files, obtained by Prokka, have been uploaded to the web-
server, the outputs (both tabular and aminoacidic FASTA sequences) have been 
downloaded for downstream analysis. All FASTA sequences were concatenated and 
clustered using CD-HIT [168], with both coverage and identity percentage set at 95%, to 
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obtain a set of homologous protein clusters (PCs). Coordinates obtained by the tabular 
output were imported in R, and a genome map of the distribution of the islands was drawn 
using the package genoplotR. To identify the genomic islands, PCs have been searched on a 
custom dataset of 23 known genomic islands (nucleotide sequences) using tblastn. 
Ubiquitous PCs that could not be assigned to any of the known GIs were searched using 
blastp on the whole nr (restricting the search to P. aeruginosa). To determine whether 
non-ubiquitous PCs distributed according to the phylogenetic structure of the population, 
we ran the analysis phylo.d (form the r-package caper) [169]. Patterns of gain and loss 
through time were evaluated using linear models on the presence/absence matrix.  
A rooted phylogenetic tree, based on the distribution of SNPs in the core genome, was then 
obtained using BEAST V1.8 [170]. 
In silico determination of the O-antigen was performed using the Pseudomonas 
aeruginosa serotypes (PAst) script (https://github.com/Sandramses/PAst).  
 
3.1.3. MLST 
In silico MLST analysis was performed with MLST 1.8 (Centre for Biological Sequence 
Analysis, Technical University of Denmark, Copenhagen). The algorithm eBURST was 
used to calculate evolutionary closeness among clonal isolates [171][172] 
(http://eburst.mlst.net/). 
 
3.1.4 Comparative sequence analysis 
Genes codifying for factors involved in virulence were extracted from the virulence factor 
database, VFDB [173]. Gene sequences were compared within the clonal lineage with 
BioEdit v7.0.5 (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) to determine the 
occurrence of sequence variants.  
Insertions and deletions and single nucleotide substitutions leading to frameshift 
mutations or premature stop codons were considered relevant for this study. 
  
3.1.5. Phenotypic assays 
 
3.1.5.1. Mucoidy 
All 40 strains were inoculated onto PIA (Pseudomonas Isolation Agar) plates (Becton-
Dickinson, Franklin Lakes, NJ, USA) and visually inspected for mucoidy 
(presence/absence of a mucoid phenotype) after 48 hours [174].  
 
3.1.5.2. Motility assay 
Swarming and twitching media were prepared using tryptic soy broth (TSB, Oxoid) 
respectively with 0.5% agar and 1% agar. 
Single colonies were picked and inoculated on agar plates and incubated for 15 h at 37° C 
and for 16 h at 37° C for swarming and twitching test respectively. Twitching plates were 
additionally incubated at room temperature (RT) for 48 h; motility was indicated by the 
formation of a halo around the colony [175]. 
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3.1.5.3. Protease production 
500 ml of 4% agar containing 8 g of brain heart infusion (BHI) (Sigma-Aldrich) medium 
was autoclaved at 121° C and subsequently mixed with 500 ml of 20% skim milk solution 
(pre-autoclaved at 118° C for 10 minutes) (Sigma-Aldrich)for a final content of 2% agar and 
10% milk in BHI. After thorough mixing, the medium was poured into 150 x 15 mm Petri 
dishes. Bacteria were inoculated onto the agar surface and incubated at 37° C for 24 hours. 
The diameter of milk turbidity clearing surrounding each colony was measured [176]. 
 
3.1.5.4. Biofilm formation assay 
Biofilm formation was assessed by the crystal violet staining assay with minor 
modifications [177]. Briefly: isolates were grown on LB ON at 37° C. Pellets were collected 
by centrifugation and re-suspended in M63 liquid medium (Amresco, Solon, OH, USA) to 
a final OD600 of 0.05. Ten µl of the cultures were then added to 90 µl of the M63 medium 
in a 96-well U-bottom microtiter plate (Costar, Washington, DC, USA). After 24 h of static 
incubation at 37° C, supernatants were removed and OD600 was measured to determine the 
cell density of planktonic bacteria. 
Cells attached to the microtiter wells through biofilm were washed twice with H2O Milli-Q 
to remove unattached and dead cells and then stained with 150 µl of an aqueous solution of 
0.1% crystal violet (Sigma-Aldrich) for 15 min. Biofilm was washed again with H2O Milli-Q, 
dried, resuspended in 125 µl of 30% acetic acid and incubated for 15 min. OD550 of 
resuspended biofilm was determined and normalized to the OD600 of corresponding 
planktonic cells. The assay was repeated at least three times per isolate. 
 
3.1.5.5. Mutation frequency  
A single P. aeruginosa colony was grown in 5 ml of LB ON at 37°C. Aliquots from serial 
dilutions were then plated on LBA plates with and without rifampicin (300 µg/ml) (Sigma-
Aldrich) and counted after 36 h at 37°C. The mutation frequencies on rifampicin were 
determined relative to the total count of viable organisms plated according to previously 
established criteria [72]. The assay was repeated in triplicate for each isolate. 
 
3.1.6. Antibiotic susceptibility  
Sensititre GRAM™ Negative Plate Format (Thermo Scientific, Waltham, MA, USA) panels 
were used to assess resistance/susceptibility for Amikacin, Cefepime, Ceftazidime, 
Ciprofloxacin, Colistin, Doripenem, Fosfomycin, Gentamycin, Imipenem, Levofloxacin, 
Meropenem, Piperacillin/Tazobactam. 
 
3.1.7. Statistical analysis 
In the phenotypic assays, Spearman’s correlation coefficient was used to study the 
correlation between the phenotypes and the time of isolation of the samples, and the 
correlation between phenotypes. 
The R function used is cor.test and the script is: 
>cor.test(as.numeric(phenotypes$Isolation_date), phenotypes$#Phenotype, 
method="spearman"). 
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Phenotypic data were plotted as a function of the isolation time. Graphics were drawn 
using the ggplot function within the ggplot2 package of R [178]: 
>ggplot(phenotypes, aes(Isolation.date, #Phenotype)) + geom_point() + geom_smooth() 
+ geom_text(aes(label=rownames(phenotypes)), hjust=0, vjust=0) 
This scrip returns a scatter plot with a trend line calculated on the bases of a smoothed 
conditional mean. 
Significance of changes over time of protease production, biofilm formation and swarming 
motility were also evaluated with Wilcox test. 
 
3.2. Results 
 
3.2.1. Whole Genome Sequencing 
Longitudinal studies are a key tool to understand pathoadaptive evolution of Pseudomonas 
aeruginosa in CF lung. In our study, 40 P. aeruginosa isolates isolated from a single cystic 
fibrosis male patient were sequenced on the Illumina MiSeq platform and assembled using 
SPAdes version 3.1.0.  
The number of contigs per genome ranged from 53 for TNCF_151 to 356 for TNCF_6. 
Mean draft genome size was 6.6 Mb, with slight variations from 6.545 Mb to 6.653 Mb in 
TNCF_12 and TNCF_101, respectively, with a mean GC content of 66.28%. The N50 of the 
draft genomes was in average 179.843 bp, ranging from 30.645 in TNCF_6 to 378.317 bp 
in TNCF_151 (Table 2). 
Genomes encoded for an average of 6151 putative ORFs with an SD of 29 (from 6052 to 
6219 in TNCF_12 and TNCF_6, respectively), with about 713 of them carrying a signal 
peptide; the average number of tRNA per genome was 60 (SD 4), and only one tmRNA per 
genome was identified. 
O-antigen in silico serotyping revealed that all the isolates belonged to the serotype O6, 
one of the most commonly found among CF isolates. 
Genome sequence data for all the 40 isolates were deposited and publicly released [179]. 
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Table 2. Genome statistics of the 40 P. aeruginosa CF isolates. N50 is the length of the shortest 
contig which, along with the larger contigs, contains half of the genome sequences. 
 
 
 
3.2.1.1. In Silico MLST Genotyping 
To understand clonal relationship among isolates, in silico MLST analysis, performed with 
MLST 1.8, revealed a characteristic single clonal population dominated by a previously 
characterized sequence type (ST390, 36 isolates), and a small number of new, closely 
related ST variants: ST1864 (six isolates: TNCF_16, TNCF_85, TNCF_88M, TNCF_101, 
TNCF_133_1, TNCF_151M), ST1923 (three isolates: TNCF_155_1, TNCF_165, TNCF_176) 
and ST1863 (one isolate: TNCF_69). The novel variants were deposited in the PubMLST 
database (https://pubmlst.org/). Eburst analysis of the sequence types indicated that 
strain 390 was the founder, while 1863, 1864, and 1923 directly descended from 390 and 
differed from it at a single locus (Fig. 6). 
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Figure 6a. E-burst analyses. Strain 390 was identified as founder; 1863, 1864 and 1923 directly 
descended from 390 and differed from it at a single locus. 
 
3.2.1.2. Phylogenetic analyses 
The distribution of SNPs in the core genome was analysed using BEAST to reconstruct the 
evolutionary history of the lineage and to examine the relationships between the isolates.  
The tree topology indicates that the population is composed by two main clusters: the first 
one comprised nearly all the early clones (13 out of a total of 17 strains isolates sampled 
between 2007 and 2008), whereas the majority of the late isolates branched within the 
second cluster (17 out of a total of 23 isolates sampled between 2010 and 2014). The six 
ST1864 isolates fall in the cluster with ST390 early isolates, while the three ST1923 isolates 
and the ST1863 one group in the cluster with the late ST390 isolates sampled between 
2010 and 2014 (Fig. 6b). 
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Figure 6b. Rooted phylogeny of the P. aeruginosa population. The tree was built on core genome 
SNPs obtained using BEAST V1.8 with ten independent runs of 109 steps using the relaxed clock model. The 
right panel reports the date of sampling and the Sequence Type of each isolate. 
 
3.2.1.3. Core and accessory genome analyses 
Previous studies have shown that the genomes of P. aeruginosa isolates are usually highly 
conserved, with a small accessory genome containing about 10% of total coding sequences 
[180][181].  
The pangenome of our population comprised 7035 genes, with nearly 85% of the genes 
shared between all the isolates (5972 genes). Among these, 5608 were core genes present 
in 39-40 isolates, and 364 were soft core genes found in at least 38 isolates (Fig. 7). A total 
of 1063 genes (15%) belonged to the accessory genome. Among these, 264 were shell genes 
present in at least six isolates, and 787 were cloud genes identified in less than six strains. 
Among the latter genes, 555 were found to be present only in one isolate. The average 
number of accessory genes per genome was 516, with TNCF_12 being the isolate with the 
minor portion of the accessory genome (415 genes) and TNCF_6 the one with the largest 
accessory genome (583 genes), consistent with the higher length of its genome.  
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Figure 7. Core and accessory genome proportions in the P. aeruginosa population. Genomic 
portions present in 38 or 39 isolates out of 40 (soft core) were considered as core genes in the text due to the 
draft assembly of the genomes.  
 
Tree topology of Figure 8 shows wide collapse at the root, and the presence of   three major 
lineages: a lineage includes 31 out of 40 isolates (the bulk of the population), a second 
lineage with the isolates TNCF_23, TNCF_10 and TNCF_42M, monophyletic also in the 
SNP-based tree, and a third lineage comprises TNCF_16, TNCF_7M, TNCF_4M, 
TNCF_10M, TNCF_32M, TNCF_151M. TNCF_6 also resulted to be the strain with the 
most diverse accessory genome, in agreement with its high number of unique regions.  
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Figure 8. Phylogenetic tree based on the distribution of accessory genes in the P. aeruginosa 
population. The analysis was performed using the hclust() function from the base R package; core genes 
have been removed from the analysis to improve the resolution of the picture. 
 
Clustering of isolates based on the composition of the accessory genome (Fig. 9) revealed a 
group of 11 highly similar genomes comprising both early and late isolates, eight belonging 
to the dominant ST390 type (TNCF_10, TNCF_13, TNCF_23, TNCF_23M, TNCF_32, 
TNCF_42, TNCF_42M, TNCF_49M) and three belonging to the derived ST1864 
(TNCF_16, TNCF_88M and TNCF_133_1). Accordingly, the number of accessory genes in 
each genome of this cluster was remarkably homogeneous, ranging from 488 to 511 genes 
in TNCF_16 and TNCF_10, respectively. 
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Figure 9: Heatmap derived from the presence/absence matrix of accessory genes within the 
population.  
 
 
3.2.1.3. Identification of genomic islands  
Several comparative genomic studies of P. aeruginosa have shown that most inter-strain 
diversity is due to the presence of regions of genomic plasticity (RGPs) or genomic islands 
(GIs) often acquired by horizontal gene transfer [182][183][37].  
The distribution of Protein Clusters (PCs) was very skewed towards the two extremes, that 
is PCs were either ubiquitous or isolate-specific; 87 PCs, belonging to six genomic islands, 
were ubiquitous in the population (Fig. 10). The analysis done with tblastn on our custom 
dataset of known GIs detected four PCs (with identity > 80% and low e-value < 4.7 e80) 
putatively belonging to the island LESGI-1 [49], two PCs (id > 85%, e-value < 1.7 e46) were 
assigned to LESGI-3 [184], while three PCs (id > 90%, e-value < 5.3 e80) were assigned to 
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the island PAGI-2 [50]. Twenty-one ubiquity PCs, belonging to the three unidentified 
genomic islands were searched, using blastp, in the non-redundant NCBI database 
restricting the search to P. aeruginosa. Most PCs found matches with hypothetical 
proteins, only six PCs found matched with the following annotated proteins: YqaJ-like 
viral recombinase domain cl09232 (WP_031641785), recombination protein RecT 
(WP_019682741), Resolvase (EJY58266), serine recombinase (WP_070330427), DNA 
ligase (NAD(+)) LigA (WP_003114675), N-acetyltransferase (WP_003096122). 
 
 
 
Figure 10: Genomic map showing the position of each genomic island on each genome. 
Homologous regions are highlighted in green.  
 
3.2.1.4. Variants and SNPs analysis 
We then looked at the distribution of variants in the core genome of the population. Data 
relative to insertions/deletions were not considered as the draft nature of the genomes 
could bias the output of the program. Each isolate contained a total of 27,249 ± 3,300 
single nucleotide variations. In particular, variants per genome ranged from 12,983 to 
29,744 in the isolates TNCF_7M and TNCF_165, respectively, with a median number of 
28,668 nucleotide variations per genome (as in TNCF_23M and TNCF_32) (Table 3).  
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Table 3. Analysis of SNPs in the population. 
 
 
 
To investigate polymorphisms that presumably have an impact on the adaptive process of 
the isolates, we extracted non-synonymous polymorphisms classified as high impact 
variants (i.e. variants resulting in protein truncation, loss of function or triggering 
nonsense-mediated decay). The number of high impact variations, based on the complete 
genome sequence of the isolates (both core and accessory genome), considerably varied in 
the population, ranging from 6 in the early isolate TNCF_7M to 167 in the late isolate 
TNCF_175 (Table 4).   
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Table 4. High impact variations in the population. 
 
 
 
 
We performed a Cluster of Orthologous Groups (COG) analysis wherein we assigned the 
genes in which high-impact variants were found to their respective COG categories to 
determine whether the majority of variants fell into few functional categories or were 
randomly distributed among all of them. The percentage of genes assigned to each COG is 
shown in Figure 11. Mutations occurred primarily (8%) in genes involved in transcription, 
followed by the following COG categories: amino acid transport and metabolism, inorganic 
ion transport and metabolism, signal transduction mechanisms and general functions (7% 
each). A large proportion of genes (28%) were not assigned to any COG category but were 
classified as genes with unknown function. The remaining genes were distributed into all 
the functional categories, with proportions reflecting those found in the analysis of whole 
genomes. 
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Figure 11. Percentages of genes assigned to each COG. 
 
3.2.1.5. Polymorphisms in the core genome of the population 
We then extended the analysis to variants in the core genome with high and moderate 
impact (non-disruptive variants that might change protein effectiveness). These ranged 
from 132 (TNCF_7M) to 394 (TNCF_167, TNCF_175) per genome, with a mean of 270 
(Table 3). Moreover, an analysis of the distribution of variants in the population (Fig. 12) 
revealed a cluster of 13 isolates (TNCF_10, TNCF_13, TNCF_16, TNCF_23, TNCF_23M, 
TNCF_32, TNCF_42, TNCF_42M, TNCF_49M, TNCF_85, TNCF_88M, TNCF_101, 
TNCF_133_1) with a high similarity in their variants pattern. One isolate, TNCF_7M, 
stands out in the distance matrix, probably due to the lowest number of SNPs present in 
the genome. 
Eight genes belonging to the core genome carried high-impact variants (Table 4). 
Interestingly, four of them have unknown function, while the known ones were: nail, lspA, 
aaltP, pcoA. 
Within the whole population, a total of 675 different genes carried mutations with 
moderate impact within the core genome (Table 4). The distribution of these variants was 
consistent with population structure (Fig. 12). Focusing on the moderate impact 
polymorphisms in the core genome of the population, we found 20 genes with three or 
more of such variations in the population (Table 5), which might be indicative of loci under 
selective pressure.  
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Figure 12. Analysis of the distribution of variants in the population. 
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Table 5. Core genes with the highest number of SNPs in the population. 
 
Gene name Product name Variations 
(n.) 
gyrB DNA gyrase subunit B 5 
pvdL non-ribosomal peptide synthase, pyoverdine biosynthesis 5 
15595766 * hypothetical protein 4 
aruF subunit I of arginine N2-succinyltransferase = ornithine N2-
succinyltransferase 
3 
ftsJ cell division protein FtsJ 3 
chpA component of chemotactic signal transduction system 3 
gidA glucose-inhibited division protein A 3 
glnE glutamate-ammonia-ligase adenylyltransferase 3 
gltB glutamate synthase subunit alpha 3 
nagE N-Acetyl-D-Glucosamine phosphotransferase system 
transporter 
3 
parE DNA topoisomerase IV subunit B 3 
pmrB two-component regulator system signal sensor kinase PmrB 3 
cbrA two-component sensor CbrA 3 
15595416 * probable aldehyde dehydrogenase 3 
15595440 * probable transcriptional regulator 3 
15596248 * probable transporter 3 
15596746 * probable cation-transporting P-type ATPase 3 
15597654 * hypothetical protein 3 
15599121 * probable major facilitator superfamily (MFS) 
transporter 
3 
15597414 * hypothetical protein 3 
The 20 genes listed above belong to the core genome and have at least three different polymorphisms 
with a moderate impact on the encoded protein according to Snippy analysis [185]. Genes under non-
neutral pressure are in bold. * Corresponding gene accession number in the reference strain PAO1, 
when the gene name does not exist. 
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3.2.2. Phenotypic and genotypic characterization 
Cystic fibrosis P. aeruginosa strains undergo phenotypic and genotypic changes during the 
switch from acute to chronic lung infection but the relative roles of these changes in 
pathogenesis and persistence are still not entirely understood [186]. These adaptations 
likely occur in response to the host airway environment, immune system components, and 
antibiotics [23].  
We have therefore analysed our collection for several phenotypic traits. In the phenotypic 
analyses, an extra strain was included, VrPa97: this isolate was an acute-infection strain 
coming from a wound swab and it was isolated from a patient at Verona hospital; the strain 
was genotypically closely related to our patients’ isolates, since it belonged to the Sequence 
Type ST390. This isolate predictably showed all the characteristics of acute-infection 
strain.  
 
3.2.2.1. Antibiotic resistance profiles  
Susceptibility to 12 antibiotics was tested for all isolates of the population (Table 6). All 
isolates were susceptible to Colistin, and nearly all the early isolates were susceptible to 
almost all the antibiotics tested. On the other hand, multidrug-resistant phenotypes 
dramatically increased over time in the persistent population. Among early strains isolated 
in 2007 and 2008, TNCF_4M was found to be susceptible to all antibiotics, while 
TNCF_7M, TNCF_10, TNCF_10M and TNCF_42M had an intermediate resistance profile 
only to Cefepime. Four early strains were found to have an MDR phenotype: TNCF_3, 
TNCF_6, TNCF_12, TNCF_14 were resistant to all the antibiotics tested with the exception 
of Colistin. Among 23 strains isolated between 2010 and 2014, only two of them, 
TNCF_88M and TNCF_151M, both belonging to ST1864, did not show an MDR 
phenotype: TNCF_88M, isolated in December 2010, was susceptible to eight antibiotics, 
with an intermediate profile to Cefepime and resistant to Ciprofloxacin, Levofloxacin, 
Fosfomycin and Piperacillin/Tazobactam, whereas TNCF_151M, isolated in May 2013, was 
found to be susceptible to 10 antibiotics, with an intermediate profile for Cefepime, and 
was resistant only to Amikacin. 
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Table 6. Antibiotic susceptibility profiles of the P. aeruginosa population. Resistance is 
highlighted in red, susceptibility in green, and intermediate profile in yellow. Resistance and susceptibility 
were determined according to the EUCAST clinical breakpoint tables. Resistant, intermediate and 
susceptible isolates are highlighted in red, yellow, and green, respectively. Acronyms are: AMI, Amikacin; 
GEN, Gentamicin; IPM, Imipenem; MEM, Meropenem; DOR, Doripenem; CAZ, Cefepime; FEP, 
Ceftazidime; CIP, Ciprofloxacin; LVX, Levofloxacin; FOS, Fosfomycin; CST, Colistin; TZP, 
Piperacillin/Tazobactam. 
 
Isolate AMI GEN IPM MEM DOR CAZ FEP CIP LVX FOS CST TZP 
TNCF_3 
            TNCF_4M 
            TNCF_6 
            TNCF_7M 
            TNCF_10 
            TNCF_10M 
            TNCF_12 
            TNCF_13 
            TNCF_14 
            TNCF_16 
            TNCF_23 
            TNCF_23M 
            TNCF_32 
            TNCF_32M 
            TNCF_42 
            TNCF_42M 
            TNCF_49M 
            TNCF_68 
            TNCF_69 
            TNCF_76 
            TNCF_85 
            TNCF_88M 
            TNCF_101 
            TNCF_105 
            TNCF_106 
            TNCF_109 
            TNCF_130 
            TNCF_133 
            TNCF_133_1 
            TNCF_151 
            TNCF_151M 
            TNCF_154 
            TNCF_155 
            TNCF_155_1 
            TNCF_165 
            TNCF_167 
            TNCF_167_1 
            TNCF_174 
            TNCF_175 
            TNCF_176 
            VrPa97             
 
Genomic analyses of the population showed a correlation between the evolution of 
antibiotic resistance profiles, MLST sequence types, and phylogenetic relationships (Fig. 
13). We further investigated the MDR isolates in comparison to the susceptible ones, 
looking specifically at P. aeruginosa genes involved in antibiotic resistance and 
susceptibility. Non-synonymous mutations were found in gyrB, mexG, parC, parE and 
pmrB, while a deletion,  ∆C437, was found in oprD (Table 7). 
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Figure 13: Comparison of population structure with antibiotic susceptibility profiles. The tree 
topology is the same as shown in Fig. 6b. The inner part of the figure represents the phylogenetic tree with 
demarcation line between early and late strains. Early strains are highlighted in grey, whereas late isolates 
are highlighted in blue. Black branches of the tree, ST390; red,  ST1864; green, ST1923; blue, ST1863. 
Antibiograms are reported as follows: red dots, resistance to the antibiotic considered; green dots, 
susceptibility; yellow dots, intermediate susceptibility phenotype.  
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Table 7. Variations in genes involved in antibiotic resistance. 
 
Gene Nt 
mutation 
Variation Isolates 
gyrB G1404-T E468-D TNCF_3, TNCF_6, TNCF_12, TNCF_13, TNCF_14, 
TNCF_68, TNCF_69, TNCF_76, TNCF_85, TNCF_88M, 
TNCF_101, TNCF_105, TNCF_106, TNCF_109, 
TNCF_130, TNCF_133_1, TNCF_151, TNCF_155, 
TNCF_165, TNCF_167, TNCF_167_1, TNCF_174, 
TNCF_175, TNCF_176 
T2245-C S749-P TNCF_10, TNCF_10M, TNCF_23, TNCF_23M, TNCF_32, 
TNCF_32M, TNCF_42, TNCF_42M, TNCF_49M 
mexG C151-T P51-S  TNCF_3, TNCF_12, TNCF_68, TNCF_76, TNCF_85, 
TNCF_88M, TNCF_105, TNCF_106, TNCF_109, 
TNCF_130, TNCF_133, TNCF_151, TNCF_155, 
TNCF_165, TNCF_167, TNCF_167_1, TNCF_174, 
TNCF_175, TNCF_176 
oprD ∆C437 frameshift TNCF_3, TNCF_6, TNCF_12, TNCF_68, TNCF_69, 
TNCF_101, TNCF_105, TNCF_106, TNCF_133, 
TNCF_155, TNCF_165, TNCF_167, TNCF_167_1, 
TNCF_174, TNCF_175, TNCF_176 
parC A509-G N170-S  TNCF_3, TNCF_12, TNCF_14, TNCF_68, TNCF_76, 
TNCF_101, TNCF_105, TNCF_106, TNCF_109, 
TNCF_130, TNCF_151, TNCF_155, TNCF_165, TNCF_167, 
TNCF_167_1, TNCF_174, TNCF_175, TNCF_176 
parE T88-C R30-C TNCF_69, TNCF_105, TNCF_106, TNCF_133, TNCF_155, 
TNCF_155_1, TNCF_165, TNCF_167, TNCF_167_1, 
TNCF_174, TNCF_175, TNCF_176 
G176-A H59-R TNCF_69, TNCF_105, TNCF_106, TNCF_133, TNCF_155, 
TNCF_155_1, TNCF_165, TNCF_167, TNCF_167_1, 
TNCF_174, TNCF_175, TNCF_176 
The variations listed above are present only in the MDR isolates and are, therefore, putatively involved 
in the acquisition of the MDR phenotype. Nt, nucleotidic. 
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3.2.2.2. Functional phenotypic assays and their associated genes. 
To assess how Pseudomonas aeruginosa virulence traits eventually changed over time in 
the course of chronic infection, a number of phenotypic assays were performed, including 
swarming and twitching motility, mucoidy, protease secretion, and biofilm production. 
Twelve isolates (30%) produced alginate and had a mucoid phenotype; eight isolates (20%) 
showed swarming motility and no one twitching motility; protease secretion was observed 
in 4 isolates (10%); 17 isolates (42.5%) produced a detectable amount of biofilm; 23 
isolates (57.5%) were hypermutable (Table 8). These analyses served as a basis for the 
selection of few strains for further characterization: TNCF_23, one of the earliest isolates, 
showed all typical acute-infection related phenotypic features (except for twitching 
motility) and was susceptible to all the antibiotics tested with the exception of Cefepime. 
The late isolate TNCF_175 showed instead all typical characteristics of a chronic-infection 
strain, and it was resistant to most antibiotics.  
Sequences of the virulent genes associated with the screened phenotypes were examined to 
tentatively associate the variations observed in the phenotypes with mutations in the 
genomes. Sequence analysis revealed both synonymous and nonsynonymous single 
nucleotide polymorphisms (data not shown), non-synonymous mutations leading to the 
insertion of stop codons, frameshift mutations and deletions of single genes or entire 
operons. Main genotypic differences between strains TNCF_23 and TNCF_175 are 
presented in Table 9. 
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Table 8. Phenotypic assays. Qualitative assessment of mucoid phenotype is reported, as well as 
quantitative measurements of swarming, twitching, protease production and biofilm formation assays. 
Positive phenotypes are in green. 
 
Isolate 
Date of 
isolation 
ST Mucoidy 
Swarming (cm) 
Twitching 
Protease 
secretion (cm) 
Biofilm production 
(OD 695/600) 
Hypermutability 
Mean SD Mean SD Mean SD  
TNCF_3 
13/04/2007 
390 NO 0 0 0 0 0 0.2538 0.2767 YES 
TNCF_4M 390 YES 2.5333 0.4933 0 0 0 0.0266 0.0392 NO 
TNCF_6 
29/05/2007 
390 NO 0 0 0 0 0 0.1719 0.1415 YES 
TNCF_7M 390 YES 0 0 0 0 0 0.0185 0.0163 NO 
TNCF_10 
26/07/2007 
390 NO 0 0 0 8.3333 0.5774 0.0059 0.0098 NO 
TNCF_10M 390 YES 0 0 0 0 0 0.0132 0.0187 NO 
TNCF_12 04/09/2007 390 NO 0 0 0 0 0 0.0563 0.0381 YES 
TNCF_13 
05/09/2007 
390 YES 1.1667 0.3786 0 0 0 0.0049 0.0075 NO 
TNCF_14 390 NO 0 0 0 0 0 1.1492 1.4577 YES 
TNCF_16 24/09/2007 1864 YES 0.9900 0.4278 0 0 0 0.0232 0.0246 NO 
TNCF_23 
17/10/2007 
390 NO 0 0 0 7.3333 0.5774 0.0056 0.0092 NO 
TNCF_23M 390 YES 0 0 0 0 0 0.0046 0.0074 NO 
TNCF_32 
23/11/2007 
390 NO 0 0 0 0 0 0.0294 0.0641 NO 
TNCF_32M 380 YES 0 0 0 0 0 0.0040 0.0072 NO 
TNCF_42 
31/01/2008 
390 NO 3.3333 0.2887 0 5.3333 0.5774 0.0032 0.0051 NO 
TNCF_42M 390 YES 0.8667 0.1155 0 3.0000 0 0.0035 0.0042 NO 
TNCF_49M 05/09/2008 390 YES 0 0 0 0 0 0.0136 0.0236 NO 
TNCF_68 02/08/2010 390 NO 3.200 0.2000 0 0 0 0.1404 0.0860 YES 
TNCF_69 22/03/2010 1863 NO 0 0 0 0 0 0.3606 0.2108 YES 
TNCF_76 09/06/2010 390 NO 0 0 0 0 0 53.8531 16.8565 YES 
TNCF_85 08/11/2010 1864 YES 2.0000 0.2000 0 0 0 0.0649 0.0783 NO 
TNCF_88M 14/12/2010 1864 YES 0.9167 0.3488 0 0 0 0.0177 0.0188 NO 
TNCF_101 30/06/2011 1864 NO 0 0 0 0 0 0.1535 0.0999 YES 
TNCF_105 25/08/2011 390 NO 0 0 0 0 0 2.3635 2.2542 YES 
TNCF_106 15/09/2011 390 NO 0 0 0 0 0 0.7177 0.5608 YES 
TNCF_109 30/09/2011 390 NO 0 0 0 0 0 1.2620 1.6300 YES 
TNCF_130 19/07/2012 390 NO 0 0 0 0 0 1.4477 1.3660 YES 
TNCF_133 
14/09/2012 
390 NO 0 0 0 0 0 0.0336 0.0598 YES 
TNCF_133_1 1864 NO 0 0 0 0 0 0.0086 0.0119 NO 
TNCF_151 
05/04/2013 
390 NO 0 0 0 0 0 4.4742 2.2776 YES 
TNCF_151M 1864 YES 0 0 0 0 0 0.0176 0.0087 NO 
TNCF_154 29/04/2013 390 NO 0 0 0 0 0 0.1406 0.1426 YES 
TNCF_155 
06/05/2013 
390 NO 0 0 0 0 0 0.0046 0.0124 YES 
TNCF_155_1 1923 NO 0 0 0 0 0 0.9051 1.1274 YES 
TNCF_165 23/09/2013 1923 NO 0 0 0 0 0 0.0113 0.0257 YES 
TNCF_167 
03/10/2013 
390 NO 0 0 0 0 0 0.1702 0.2495 YES 
TNCF_167_1 390 NO 0 0 0 0 0 19.7247 19.1355 YES 
TNCF_174 24/04/2014 390 NO 0 0 0 0 0 0.0892 0.1629 YES 
TNCF_175 23/06/2014 390 NO 0 0 0 0 0 0.2394 0.3112 YES 
TNCF_176 11/08/2014 1923 NO 0 0 0 0 0 0 0 YES 
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Table 9. Genotypic differences between TNCF_23 and TNCF_175 and related phenotypic 
effects. 
 
GENE TNCF_23 TNCF_175 MUTATION EFFECT 
mucA Deletion in C34 Wild-type Mucoid phenotype 
algQ Wild-type ∆G40 Dysregulation of 
Pyoverdine genes; 
changes in quorum 
sensing 
oprD Wild-type ∆C436 Acquisition of resistance 
to carbapenems 
pscG Wild-type InsG170 Effector protein of Type 
3 Secretion System 
Piv Wild-type InsC200 Changes in protease IV 
activity 
tssK3 Wild-type C958T Q320STOP Baseplate component of 
Type 6 Secretion System 
fliR  C382T Motility 
flhA  C2116T Motility 
pvdL  T7837C Iron uptake 
prpL Wild type insC205 Secretion system and 
toxins 
pscG Wild-type insG160 Secretion system and 
toxins 
 
 
3.2.2.3. Analysis of phenotype correlation 
Correlation among the different phenotypes and relationship between phenotypes and 
time of isolation of the strains were examined. The analyses were performed calculating 
the Spearman’s correlation coefficient (rho). To visualize the variation of the phenotype as 
a function of time, phenotypic data were plotted with the isolation date of the samples. In 
figures 14a-e, each dot represents a P. aeruginosa isolate, and the colour of the dot 
corresponds to its ST. The blue trend line represents the smoothed conditional mean of the 
phenotypic values, while the shaded area highlights the confidence interval around the 
smoothed line. 
The Spearman’s correlation test indicates that the mucoid phenotype (Fig. 14a) has a 
significant inverse correlation (rho = -0.407, p = 0.009); mucoid isolates were indeed 
concentrated mainly in the first half of the plot, except for TNCF_151M. 
Although swarming motility (Fig. 14b) was observed mainly in early isolates, there was no 
significant correlation between swarming motility and time of sampling (rho = -0.272, p = 
0.090). 
Only a few of the earliest strains showed secreted proteolytic activity (Fig. 14c). However, 
the regression line didn’t show a marked trend. In fact, there wasn’t any significant 
correlation between the two parameters studied (rho = -0.251, p = 0.118). 
An increasing biofilm formation trait occurred from 2011 to the first half of 2013, but after 
that, biofilm formation decreased. Spearman’s coefficient indicated no significant 
correlation (rho = 0.202, p = 0.211) between biofilm formation and time of sampling (Fig. 
14d). 
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Hypermutable phenotype showed a significant correlation (rho = 0.500, p = 0.001) with 
the time of isolation (Fig. 14e); this trait was present mainly in late isolates. 
 
 
 
 
Figure 14a. Evolution of mucoid phenotype as a function of time of isolation. The plot was drawn 
using the R-package ggplot2. The function geom_smooth() was used with all default parameters. Blue line, 
regression line fitting the data; grey shaded area, 95% confidence interval. Orange dots, ST390 isolates; 
green, ST1863; blue, ST1864; purple, ST1923. 
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Figure 14b. Evolution of swarming phenotype as a function of time of isolation. 
 
 
 
 
Figure 14c. Evolution of protease secretion phenotype as a function of time of isolation. 
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Figure 14d: Evolution of biofilm formation phenotype as a function of time of isolation. 
 
 
 
Figure 14e: Evolution of hypermutability phenotype as a function of time of isolation. 
 
To compare early against late isolates, a Wilcox analysis was performed on quantitative 
phenotypes, namely protease production, swarming motility and biofilm formation. 
Significative results were obtained for biofilm formation and protease secretion: later 
strains produced significantly more biofilm than the early isolates, and only four samples 
out of 40 (all early) showed proteolytic activity. Eight isolates out of 40 presented 
swarming motility, among which three late strains and five early isolates; nevertheless, the 
test performed on swarming motility did not reveal a significant trend (Figs. 15a-c). 
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Figure 15a. Wilcox test on swarming motility data. 
 
 
 
 
Figure 15b. Wilcox test on protease secretion data. 
 
 
 
 
Figure 15c. Wilcox test on biofilm formation data. 
 
 
3.2.2.4. Correlation of patient data with P. aeruginosa phenotypes 
The exacerbation of lung conditions seems to correlate with the time of predominance of 
MDR, hypermutable, biofilm-forming isolates (Fig. 16, Tables 6 and 8). From January 
2010 onwards, the patient started enduring a progressive and inexorable decline in lung 
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function. In the latest stages of infection, the selected antibiotic therapy consisted of a 
combination of glycopeptides, aminoglycosides, and carbapenems. Most of the isolates 
isolated between 2010 and 2014 show resistance to aminoglycosides and carbapenems. 
 
 
Figure 16: Time course of FEV1 (Forced Expiratory Volume in the 1st second), BMI (Body Mass 
Index) and antibiotic therapy. Intravenously administered antibiotics are shown in orange while orally 
administered drugs are indicated in blue. Trendlines of FEV1 (red) and BMI (green) time courses are shown. 
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4. FUNCTIONAL STUDIES ON SPECIFIC STRAINS 
To get further insights into changes that have occurred in our population over the years, 
two strains were chosen for further characterization: 
 one early CF isolate (TNCF_23 isolated in 2007) with phenotypic traits typically 
observed at the initial stage of adaptation, including susceptibility to most antibiotics; 
 one late CF isolate (TNCF_175 isolated in 2014), clonal to TNCF_23, with traits typically 
observed in CF-adapted strains, including a multidrug-resistant phenotype. 
A third strain was included in the analyses: an acute isolate (VrPa97) isolated from a non-
CF patient, but belonging to the same Sequence Type as the two CF isolates (ST390). 
The aim was to identify additional phenotypic and functional variations within isolates 
with a very homogeneous genomic background but remarkably different phenotype, to 
possibly find new pathoadaptive mutations occurring during the course of chronic 
infection.  
 
4.1. Materials and methods 
 
4.1.1. Cell cultures and invasion assay 
A549 (human type II pneumocytes) cell line was purchased from American Type Culture 
Collection CCL-185 and cultured in DMEM (Gibco, Carlsbas, CA, USA), 10% FBS (fetal 
bovine serum) (Gibco), 2 mm l-glutamine (Gibco), 100 U/ml penicillin (Gibco), 100 mg/ml 
streptomycin (Gibco). Bacterial invasion assay was performed by using Polymixin B 
protection assay with minor modifications [187]. Pseudomonas aeruginosa strains were 
grown in TSB until mid-exponential phase (OD600 of 0.5–0.6). Cells were harvested at 4°C, 
washed twice with PBS and diluted in the tissue culture serum-free medium. The cell 
suspension was used to infect cell monolayers (approximately 80% confluence) in 24-well 
tissue culture plates at a multiplicity of infection (MOI) of 100:1 (2.5x107 bacteria per 
2.5x105 cultured cells). The infected monolayers were centrifugated (800 g per 5 min) and 
incubated at 37°C in 5% CO2 for 2h to allow bacterial entry. The monolayers were then 
washed three times with PBS, and tissue culture medium containing 100 µg/ml Polymixin 
B (Sigma-Aldrich) was added. After 2 h of incubation, the cell monolayers were washed 
and lysed with H2Odd. Intracellular bacteria were quantified by plating serial dilutions of 
the lysates and the supernatants on TSB agar plates. All quantitative invasion assays were 
performed in triplicate.  
 
4.1.2. IL-8 secretion 
IL-8 was determined in supernatants collected from the cell cultures described above using 
an ELISA kit (Merck Millipore, Billerica, MA, USA). According to the manufacturer, the 
minimum detectable concentration of IL-8 is 4.4 pg/mL. 
 
4.1.3. Deletion of tssK3 in P.aeruginosa and complementation 
As shown in Table 9, tssK3, which encodes a structural protein of T6SS, is one of the 
genetic differences between TNCF_175 and TNCF_23. Specifically, TNCF_175 has a 
mutation in tssK3 that gives rise a premature stop codon (C958T Q320STOP). By impairing 
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the function of the tssK3 gene in PAO1 and PA14, the aim was to explore and explain 
phenotypic differences that have been observed between the two isolates.  
 
4.1.3.1. Creation of a mutator fragment 
Briefly, to create a clean tssK3 deletion on the chromosome of P. aeruginosa, a fragment of 
approximately 500bp on either side of the gene of interest was amplified. The 3’ primer of 
the upstream fragment (primer no.2) and the 5’ primer of the downstream fragment 
(primer no.3) contained a few bases of the gene, including the start and stop codons. 
The two fragments were joined by overlapping PCR to create a mutator fragment, which 
was cloned into pKNG101 [188], a Pseudomonas suicide vector. Subsequently, pKNG101 
was conjugated into PAO1 and PA14. 
Primer 1 (OAL4076): located 706 bp upstream tssK3. A BamHI restriction site was added, 
which is compatible with pKNG101, plus three random base-pairs, for a total of 30 bp. 
Primer 2 (OAL4077): located at the 5’ end of tssK3, it contains the start codon of the gene 
+ 18 tssK3 bp + 9 bp of the 3’ end of the gene that will match with primer 3, for a total of 
29 bp. 
Primer 3 (OAL4078): located at the 3’ end of tssK3, it contains 18 bp of the gene of interest 
and includes stop codon + five bp downstream tssK3 + 9 bp of primer 2, for a total of 32 
bp. 
Primer 4 (OAL4079): located 620 bp downstream tssK3. A SpeI restriction site was added, 
which is compatible with pKNG101, plus three random bp, for a total of 29 bp 
Primer 5 (OAL4080): located 96 bp upstream of primer 1; it is 20 bp long, and it is used to 
check if mutator fragment is integrated into the chromosome. It is 20 bp long. 
Primer 6: 108 bp downstream primer 4; it is 20 bp long, and it is used to check if mutator 
fragment is integrated into the chromosome. In is 20 bp long.  
All primers are described in Table 10. 
 
Table 10. Primers used in this study. 
Primer Sequence Purpose Source 
OAL4076 3’-AAAGGATCCAGGTGTCCGATACCGCTCATC-5’ Primer 1 for the 
creation of tssK3 
mutator fragment and 
screening  
This study 
OAL4077 3’-CTGCCTGACGGCAGCGACAACACCTAGAC-5’ Primer 2 for the 
creation of tssK3 
mutator fragment 
This study 
OAL4078 3’-GTCGCTGCCGTCAGGCAGAACACTCATACGAC-
5’ 
Primer 3 for the 
creation of tssK3 
mutator fragment 
This study 
OAL4079 3’-TATACTAGTGAACCTGTCCTTGGCGATCC-5’ Primer 4 for the 
creation of tssK3 
mutator fragment and 
screening 
This study 
OAL4080 3’-AACCAGCATGAACAGGGTCG-5’ 
 
Primer 5 for insertion 
screening 
This study 
OAL4081 3’-CTTGTGCTGCGTACTCTCGG-5’ Primer 6 for insertion 
screening 
This study 
OAL4069 3’-ATGGAATTCACGTCGAAGGGGAGTCGTAT-5’ TssK3 
complementation 
This study 
OAL4070 3’- TssK3 This study 
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CTACTCGAGGGATCCCTAGGTGTTGTCGCTGCCG-
5’ 
complementation 
Upkn 3’-CCCTGGATTTCACTGATGAG-5’ pKNG101 screening 
primer 
[189] 
Rpkn 3’-CATATCACAACGTGCGTGGA-5’ pKNG101 screening 
primer 
[189] 
M13F 3’-TGTAAAACGACGGCCAGT-5’ pBBR1MCS-4 
screening primer 
[190] 
M13R 3’-CAGGAAACAGCTATGACC-5’ pBBR1MCS-4 
screening primer 
[190] 
 
 
First, genomic DNA from TNCF_23 was extracted. Upstream and downstream fragments 
were amplified using primers 1 and 2, and 3 and 4, respectively. PCR products were 
checked on a 1% agarose gel and subsequently purified with Qiagen PCR purification kit, 
following manufacturer's instructions. PCR products were diluted 1:20 and 1.5 µl of each 
were used for the overlapping PCR using primers 1 and 4. 
After this step, PCR product was checked on an agarose gel. Mutator fragment was then 
digested using BamHI and SpeI. Mutator fragment concentration was determined with a 
Nanodrop spectrophotomer (Thermo Scientific). 
To ligate the product into pKNG101 (Fig. 17 and Table 11), a digestion of the plasmid with 
the same restriction enzymes was performed. Digestion product was checked on an 
agarose gel, and the linearized plasmid of the right size was gel-extracted. After 
determining its concentration, ligation was performed, using a vector:insert ratio of 1:3. 
pKNG101-tssK3 was then transformed into Chemically Competent CC118λpir with heat 
shock. Transformants were selected on Streptomycin 50 µg/ml LB upkn agar and a colony 
PCR with primers 1 and 4 was carried out to assess the presence of vector and insert. 
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Figure 17. pKNG101-∆tssK3. tssK3 mutator fragment is located between the sequences of the primers 
OAL_4076 (“Primer 1”) and OAL_4079 (“Primer 4”), which contain the restriction sites BamHI and SpeI, 
respectively. The plasmid also contains the sequences of its specific screening primers, Upkn and Rpkn, a 
Streptomycin resistance cassette, sacB cassette and R6K origin of replication. 
 
4.1.3.2. tssK3 deletion in PA14 and PAO1 
On the first day, overnight cultures in LB of receiver strains (PA14 and PAO1), helper strain 
(E.coli 1047 pRK2013) and donor strain (CC118λpir) were inoculated. The following steps 
were performed in parallel for both PAO1 and PA14 as receiver strains. 
On the second day, 500 µl of receiver overnight culture was incubated for 2 hours at 43°C. 
This step inactivates P. aeruginosa restriction-modification system. 20 µl spots of the 
helper strain were placed on top of 20 µl of the donor strain onto an LB plate and 
incubated for 2 hours at 37°C. After the 2 hours of incubation, 40 µl of the receiver strain 
was placed on top of one donor + helper spot (Fig. 18). Single donor, helper and receiver 
spots were also plated and incubated as controls.  
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Figure 18. Scheme of conjugation plate. 
 
After 4 hours, each patch was collected and resuspended in 500 µl TSB and subsequently 
grown for one hour at 37°. All of the donor, helper and receiver 500 µl TSB cultures were 
plated as negative controls on Vogel-Bonner Medium (VBM) with streptomycin 2000 
µg/ml (these should not grow on VBM + antibiotic). 100 and 400 µL of donor + helper + 
receiver spot were plated on two VBM plates with streptomycin.  Plates were incubated for 
36 h at 30 °C.  
On day four conjugant colonies were patched onto LB agar 20% sucrose, and then on LB 
agar Sm2000. Plates were incubated for 48h at room temperature. On day six we looked for 
no or considerably reduced growth on sucrose and normal growth on Sm2000. This 1st event 
of recombination was screened by colony PCR with the following primer pairs: Rpkn + 
primer 4, and Upkn + primer 1. 10ml LB with one upstream, and one downstream 
recombinant 1st event clone were inoculated and incubated with shaking at 30°C for 
around 4h, when the slightest amount of turbidity was visible. 100 µl of the cultures were 
then plated on LB agar 20% sucrose and incubated for 24-72h at room temperature until 
colonies appeared. 
On day 7, colonies were patched on LB agar Sm2000, PIA and LB agar in that order, and 
incubated at 37°C overnight. On day eight we looked for Sm2000-sensitive (no growth) 
clones, which instead grew on PIA and LB agar. This second event was screened from an 
LB agar plate with internal (primer 1+4) and external (5+6) primers. A couple of positive 
clones were streaked onto LB Sm2000 and LB agar in that order to confirm expulsion of the 
plasmid. Plates were then incubated at 37°C overnight. On day nine a colony PCR was done 
on single colonies from streaked out clones that didn’t grow on LB Sm2000. A positive clone 
single colony was inoculated overnight in TSB and stocked on day 10. 
 
4.1.3.3. Complementation of tssK3 in PA14 and PAO1 
The following primers for tssK3 complementation were designed (Table 10): 
• OAL4069: forward primer, composed by ATG + EcoRI site + 18 bp + 2 bp at the 
beginning of tssK3, for a total of 29 bp; 
• OAL4070: reverse primer, made of 3 bp + BamHI site + XhoI site + 19 bp at the end 
of tssK3, for a total of 34 bp. 
20 µl donor 
20 µl helper 40 µl receiver 
40 µl receiver added 
on top of helper + 
donor 
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After PCR amplification and purification of the fragment, this was digested with EcoRI and 
BamHI, as well as the plasmid pBBR1MCS-4 (Table 11), which was then gel-extracted; the 
following step was a ligation between digested plasmid and tssK3, using the same 
proportions used for tssK3 deletion (vector:insert=1:3). The vector with the gene was then 
transformed into XL-1 Blue Competent Cells, and the presence of the gene was assessed by 
colony PCR using screening primers M13F and M13R. Positive colonies were inoculated 
overnight. The following day a Miniprep (Qiagen) was performed on the cultures, and one 
plasmid was chosen to be sequenced. Sequencing confirmed the presence of tssK3 in 
pBBR1MCS-4 (Fig. 19).  
 
Figure 19. pBBR1MCS-4-tssK3. Along with tssK3, the plasmid presents several restriction sites, a LacZ 
alpha fragment, a bla cassette, and the sequences of the screening primers M13F and M13R upstream and 
downstream of tssK3 gene. 
 
To insert the plasmid into PAO1 and PA14, a similar procedure as the one used to insert 
pKNG101-∆tssK3 was followed: On day 1, overnight cultures in LB of PA14, PAO1, helper 
strain (E.coli 1047 pRK2013) and donor strain (XL1-Blue) were inoculated. On day 2, 500 
µl of receiver overnight culture was incubated for 2 hours at 43°C. 20 µl spots of the helper 
were placed on top of 20 µl of the donor strain onto an LB plate and incubated for 2 hours 
at 37°C. After the 2 hours of incubation, 40 µl of the receiver strain was placed on top of 
one donor + helper spot. Single donor, helper and receiver spots were also plated and 
incubated as controls. After 4 hours, each patch was collected and resuspended in 500 µl 
TSB and subsequently grown for one hour at 37°. All of the donor, helper and receiver 500 
µl TSB cultures were plated as negative controls on to Vogel-Bonner Medium (VBM) with 
Carbenicillin 250 µg/ml. 100 and 400 µL of donor + helper + receiver spot were plated on 
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two VBM plates with Carbenicillin.  Plates were incubated for 36 h at 30 °C. Colonies were 
screened for the presence of pBBR1MCS-4 + tssK3, and positive colonies were inoculated 
overnight. The following morning stocks of complemented strains were made. 
 
Table 11. Plasmids used in this study. 
Plasmid Purpose Source 
pKNG101 tssK3 deletion [188] 
pBBR1MCS-4 tssK3 complementation [190] 
 
4.1.4. Artificial Sputum Medium 
The media mimics the patient lung environment and is rich in amino acids, free DNA and 
mucin [191]. Therefore, by using ASM it was possible to see how CF strains grow in an 
environment that resembles cystic fibrosis lungs and to check if any differences between 
early and late isolates occur. 
 
4.1.4.1. ASM recipe 
Four grams of DNA from fish sperm (Sigma-Aldrich) were slowly added to 250 ml of 
deionized water, kept on stirrer and let dissolve; five grams of mucin (Sigma-Aldrich) were 
gradually added to 250 ml water, kept on stirrer and let dissolve; 250 mg of each 
aminoacid (Sigma-Aldrich), except cysteine and tyrosine, were added to 100 ml water, kept 
on stirrer and let dissolve; 250 mg cysteine was dissolved in 25 ml water, while 250 mg 
tyrosine was dissolved in 25 ml KOH 0.5M; 5.9 mg DTPA, 5 g NaCl and 2.2 g KCl were 
dissolved in 250 ml water. Solutions were mixed all together and 5 ml Egg Yolk emulsion 
(Sigma-Aldrich) were added. pH was adjusted to 6.9 using Tris pH 8. The mix was filled up 
to 1 l volume with sterile water. Five aliquots of 200 ml each were obtained out of 1 l, and 
the medium was autoclaved and then stored at 4°C until use. 
 
4.1.4.2. ASM assays 
Single assay: overnight LB cultures of P. aeruginosa were diluted to OD600=0.05. The 0.05 
OD600 cultures were diluted in ASM 1:100. ASM + P. aeruginosa were transferred into a 
24-well plate (Fig. 11). Once a day, 2 ml from three wells were collected and dissolved in 2 
ml Sputasol (Thermo Scientific). Seven 10-fold dilutions were performed from the diluted 
cultures. From each dilution, 10 µl were taken and plated onto LB agar as spots (Fig. 21). 
At each time point, day 0 (T0), day 1 (T1), day 2 (T2), day 3 (T3), day 5 (T5), day 7 (T7), 
colonies were counted and CFU concentration was calculated.  
Competitive assay: the same procedure was adopted as for the single assay, but using two 
strains at the same time: for each strain the overnight cultures were diluted to OD600=0.05, 
and these were subsequently diluted as following: strain 1: ASM = 1:200; strain 2: ASM = 
1:200 (both strains were inoculated in the same ASM flask). Culture obtained in this way 
was placed in a 24-well dish (Fig. 20). Every day, 2 ml from three wells were collected and 
dissolved in 2 ml Sputasol (Thermo Scientific). From the diluted cultures, seven 10-fold 
dilutions were made. From each dilution, 10 µl were taken and plated onto LB agar and LB 
agar + appropriate antibiotic: in this work, Ampicillin was used to select for TNCF_175 
against TNCF_23, and for VrPa97 against TNCF_23; Meropenem was used to select for 
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TNCF_175 against VrPa97; Imipenem was used to select for VrPa97 against PA14, 
PA14∆tssK3, PA14∆tssK3ptssK3, PAO1, PAO1∆tssK3 and PAO1∆tssK3ptssK3.  
At each time point, day 0 (T0), day 1 (T1), day 2 (T2), day 3 (T3), day 5 (T5), day 7 (T7), 
CFU were counted. Antibiotic-free plates were used to infer the total amount of CFU from 
both strains; to calculate CFU from the isolate that had been previously selected against on 
the selective plate, the formula (number of colonies on antibiotic-free plate – number of 
colonies on selective plate) was applied.  
 
 
 
Figure 20. Scheme of ASM culture in a 24-well plate. T0=day 0; T1=day 1; T2=day 2; T3=day 3; 
T5=day 5; T7=day 7. The experiment was performed in triplicates, and each day cultures from three wells 
were analysed (coloured rectangles).  
 
 
                                                                
Figure 21. Example of the scheme of 10 µl spots on a culture plate. Each quadrant corresponds to a 
dilution, and each spot corresponds to a single well. 
 
4.1.5. T6SS-mediated bacterial competition 
An Escherichia coli recipient cell was engineered by transforming E.coli DH5α cells with 
pBluescript KS(+) allowing the a-complementation of the lacZ gene. The transformed cells 
were plated on LB agar plates containing 5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
10-1 10-2 
10-3 10-4 
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(X-gal) at 40 µg/ml final concentration and Ampicillin at 100 µg/ml. Plates were incubated 
at 37 °C. The P. aeruginosa donor cells were grown on LBA overnight at 37 °C. The next 
day, an overnight liquid culture in aerated flask was prepared by inoculating a blue colony 
among the E. coli transformants in 5 ml of TSB supplemented ampicillin and incubated 
under agitation at 37°C. Single colonies of donor strains were inoculated too.  
As described by Hachani et al. [192], with minor modifications, after overnight growth, a 
cell density of 1 OD600 of each strain was harvested in a 1.5 ml tube and centrifuged at 
13.000 rpm for 1 minute. The pellets were resuspended in 100 µl of fresh TSB by gentle 
pipetting and 10 µl of each corresponding strain as a single spot were inoculated. 30 µl of 
donor and 30 µl of recipient E. coli were mixed. 20 µl of the mixes were plated as 
individual spots on an LBA plate. A bacterial killing occurred after 5 hours incubation at 
37°C. 
Readout assay was performed on LBA plates containing 40 µg/ml X-gal. Individual 
bacterial spots were collected with a sterile loop and resuspended in distinct 1.5 ml tubes 
containing 1 ml of TSB. For every strain, series of 7 times 3 tubes containing 900 µl of TSB 
were prepared and each spot was resuspended to 10-fold serial dilutions up to 10-7. These 
dilutions were spotted on LBA plates containing 40 µg/ml X-gal. For reproducibility of the 
results, 20 µl were spotted in triplicate within a quadrant (Fig. 22).      
   
 
 
 
 
 
 
 
 
Figure 22. Example of the scheme of the readout plate. Each quadrant corresponds to a dilution 
spotted in triplicate. 
 
 
For a quantification of the competition assay, 100 µl of the dilutions wear spread on LBA 
plates containing 40 µg/ml X-gal. The dilution plates were incubated in a 37 °C incubator 
overnight. 
For a qualitative assay, plates were placed in a 37 °C incubator overnight. Pictures were 
taken for the analysis: spots remaining predominantly blue indicated that E. coli had not 
been killed by P. aeruginosa. This happens when E. coli is co-cultured with a T6SS-
defective P. aeruginosa strain. A positive and a negative controls were included in this 
study: PAK∆ret (positive for T6SS) and PAK∆ret∆H1-T6SS (defective in T6SS) [192]. 
 
 
10-1 10-2 
10-3 10-4 
62 
 
4.1.6. Caenorhabditis elegans slow killing assay 
 
4.1.6.1. Nematode Growth Medium 
Caenorhabditis elegans was maintained on Nematode Growth Medium agar [41]. For 
NGM preparation and general maintenance procedures, protocols described by Stiernagle 
et al. were followed with minor modifications [193]. 23 g of Nematode Growth Medium 
(NGM) powder (US Biological, Salem, MA, USA) were dissolved in 1 L of Milli-Q water and 
the solution was autoclaved for 15 min at 121° C. The flask was cooled in a 55° C water bath 
for 15 min. Previously sterilized solutions were then added: 1 mL of 1 M CaCl2, 1 mL of 1 M 
MgSO4 and 25 mL of KPO4 buffer (108.3 g of KH2PO4, 35.6 g of K2HPO4, H2O to 1 L). 
Finally, 22 mL of complete medium were dispensed into Petri plates (100 mm diameter). 
Plates were left 2-3 days at room temperature (RT). 
 
4.1.6.2. Conservation of C. elegans  
100 µL of an E. coli OP50 liquid culture in LB-grown overnight at 37° C at 180 rpm were 
spread onto NGM plates and then incubated overnight at 37° C to allow formation of a thin 
layer.  Worms were transferred onto NGM plates with OP50 using the “chunking” method 
[193]. Briefly, a sterile scalpel was used to move a chunk of agar from an old plate to a fresh 
plate. Stocks were maintained at 20° C.   
 
4.1.6.3. Killing assay plates preparation 
5-Fluorodeoxyuridine or Floxuridine (FUdR) is an inhibitor of DNA synthesis which 
prevents C. elegans reproduction, without interfering with nematode development and 
ageing. The use of FUdR is therefore essential to avoid errors in worms lifespan evaluation.  
FUdR (Sigma-Aldrich) was added to NGM to a final concentration of 160 µM and 10 mL of 
medium were poured into 60x15mm Petri dishes.  
For each CF strain, OD600 of overnight liquid cultures was measured and subsequently 
diluted to a concentration of 1 OD/ml; 36 µL of the diluted cultures were added onto an 
NGM+FUDR plate. As a control, one plate was spread with 36 µL of a 1 OD/ml E. coli 
OP50 culture. Plates were incubated overnight at 37°C. 
 
4.1.6.4. Synchronization of C. elegans  
To synchronize worms at the first larval stage (L1) the bleaching technique was used [194]. 
The principle of this method is that adult worms are sensitive to bleach (5% solution of 
sodium hypochlorite, NaClO) and therefore die rapidly, while the eggshell protects 
embryos from dissolution.  
About 7 mL of M9 medium (Sigma-Aldrich) were poured onto NGM plates with C. elegans. 
M9 was aspirated and transferred to a 15-mL tube. This step was repeated twice. After a 1-
minute centrifugation at 1500g the supernatant was discarded. Other additional washes 
with M9 were performed until the liquid was clear. After elimination of the supernatant, 
3.5 mL of M9, 500 µL of 5 M NaOH and 1 mL of bleach were added. After vigorous 
shaking, bleach started to kill adult worms. To not damage embryos, bleach-induced death 
was observed by using a stereomicroscope to verify the dissolution of adult worms that 
normally occurs within 4 minutes. Bleach was inactivated by adding M9 to a final volume 
of 15 mL. The supernatant was discarded, and M9 was added to a final volume of 15 mL. 
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Tubes were centrifugated for 2 minutes at 1500g, and supernatant was discarded. This step 
was performed five times. After the last wash, the supernatant was discarded and about 6 
mL of M9 were added. The content of tubes was split onto 3 NGM plates. 
 
4.1.6.5. Slow killing assay 
50 worms at the L4 stage were individually transferred from an NGM plate onto an 
NGM+FUDR+bacterial strain plate using a sterilized platinum wire with the aid of a 
stereomicroscope. Plates were incubated at 20°C and the number of live nematodes was 
counted every day over a period of 20 days. A worm was considered dead when it no longer 
responded to touch. The experiment was repeated three times for each CF strain. 
 
4.1.7. Galleria mellonella killing assay 
The virulence potential of P. aeruginosa TNCF_23, TNCF_175 and VrPa97 strains was 
evaluated in Galleria mellonella larvae, according to Betts et al. [195], with minor 
modifications. Briefly, overnight cultures of P. aeruginosa grown in Trypticase Soy broth 
were washed and resuspended in PBS. Each strain was tested at doses of 103, 104, 105, and 
106 CFU/larva. Ten microliters of the bacterial suspension were injected directly into the 
hemocoel of the wax moth via the right proleg using 10 µl Hamilton syringe (Hamilton Co., 
Nevada, USA). Bacterial colony counts on Trypticase Soy agar plates were used to confirm 
inoculum size of bacterial suspensions. Control larvae were injected with 10 µl of PBS to 
measure any potential lethal effects of the injection process. An additional control group 
had no manipulation. Each experimental group consisted of 20 G. mellonella larvae, with 
each experiment repeated 3 times. After exposure, larvae were incubated in the dark at 
37°C and checked daily for survival until 96 h. Larvae were considered dead if they failed to 
respond to touch. 
 
4.1.8. Statistical analysis 
Results of all assays were plotted and analysed with GraphPad Prism version 6.0 for 
Windows (GraphPad Software, San Diego, CA, USA)[196].  
For the invasion assay and the IL-8 secretion assay, Mann-Whitney test [197] and 
unpaired t-test with Welch’s correction [198] were applied. 
For the T6SS-mediated bacterial competition test, unpaired t-test with Welch’s correction 
and Mann-Whitney test were applied. 
For the C. elegans slow killing assay, survival curves of C. elegans were plotted showing 
survival rate as a function of time and were compared with the non-parametric Log-rank 
(Mantel-Cox) statistical test [199]. 
For the G. mellonella killing assay, survival curves were plotted and differences in survival 
were calculated using the Log-rank (Mantel-Cox) test. LD50 values of P. aeruginosa 
strains were calculated by the generalized linear model, and differences were tested for 
significance by Student-t-test. P values less than 0.05 were considered as statistically 
significant. 
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4.2. Results 
 
4.2.1. Phenotypic characterization 
 
4.2.1.1. Internalization assay in A549 human cells 
During the course of chronic infection, the bacterium tends to internalize more compared 
to non-chronic strains, and this could benefit bacterial survival through evasion of host 
phagocytic- and antibody/complement-mediated killing mechanism [200]. An invasion 
assay was therefore performed using A549 epithelial lung cells. TNCF_175 seemed to 
internalize more than TNCF_23 and VrPa97, with a mean value of 3.5x103 bacteria/ml, 
while TNCF_23 showed a mean value of 2.5x103, and VrPa97 2.2x103 (Fig. 23). Despite a 
clear tendency of TNCF_175 to be more invasive than VrPa97 and TNCF_23, neither 
Mann-Whitney test nor unpaired t-test with Welch’s correction showed data significance; 
this is probably due to the low number of replicates (3). 
 
 
 
Figure 23. Internalization of P. aeruginosa in A549 cells. Concentration of invading bacterial cells 
in A549 type II pneumocytes after 2 hours of stimulation with strains VrPa97, TNCF_23 and TNCF_175. 
Measurements were performed in triplicate. 
 
4.2.1.2. Inflammation assay in A549 human cells 
Pseudomonas aeruginosa possesses a number of virulence factors (such as pilin, flagellin, 
proteases) that have been shown to increase secretion of the chemokines such as IL-8 by 
human airway epithelial cells [201][202][203]. To assess the capability of P. aeruginosa to 
induce IL-8 secretion, A549 epithelial lung cells were used. Mean values of IL-8 
production by A549 cells were 187.5 pg/ml when infected with VrPa97, 212.5 pg/ml in the 
presence of TNCF_23, and 81.3 pg/ml when infected with TNCF_175 (Fig. 24). Despite an 
apparent tendency of TNCF_175 to be less immunostimulatory than VrPa97 and 
TNCF_23, neither Mann-Whitney test nor unpaired t-test with Welch’s correction showed 
statistical significance; this is probably due to the low number of replicates (3). 
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Figure 24. Levels of IL-8 production in A549 epithelial cells infected by P. aeruginosa. 
Interleukin-8 production was quantified by ELISA after stimulation with VrPa97, TNCF_23 and TNCF_175 
for 2 hours. Measurements were performed in triplicate. 
 
4.2.2. Construction of clean mutants in tssK3 and tssK3 complementation 
By analysing the genome of TNCF_175, a stop-mutation in tssk3 was found. The gene 
encodes a T6SS structural protein that has not been characterized in depth to date. To get 
further insights on the role of the protein, clean mutants in tssK3 in the backgrounds of 
PAO1 and PA14 have been constructed. 
By conjugation, clean mutants in tssK3 and complemented strains with a plasmid 
containing constitutively expressed tssK3 were created, in the background of the reference 
laboratory strains PAO1 and PA14 (Figs. 25-26). 
 
 
 
Figure 25. PCR amplification confirming that the second recombination event has occurred to 
create a) mutants or b) wild-type PA14 and PAO1 strains. Well 1: Negative control; wells 2, 6: 
PA14∆tssK3; wells 3-5: PA14; wells 7, 9, 11: PAO1; wells 8, 10, 12: PAO1∆tssK3; well 13: PA14 wt used as 
control. 
 
a) 1392 bp 
b) 2724 bp 
3 kb 
2 kb 
1.5 kb 
kb 
1 kb 
 1     2      3      4      5      6      7      8     9     10    11    12    13    14    15   16                         
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Figure 26. PCR amplification confirming the insertion of the plasmid pBBR-4-tssK3.Wells 1-6: 
PA14∆tssK3ptssK3; wells 7-12: PAO1∆tssK3ptssK3. 
 
 
 
4.2.3. Artificial Sputum Medium (ASM) assays 
 
4.2.3.1. Bacterial growth in ASM 
To evaluate how CF strains grow in Artificial Sputum Medium, a particular medium which 
reproduces environmental conditions that are present in cystic fibrosis patients’ lungs, P. 
aeruginosa isolates were grown for seven days and growth was assessed on day 0, day 1, 
day 2, day 3, day 5 and day 7. The isolates that were grown in ASM are TNCF_23, 
TNCF_175, VrPa97, PA14, PA14∆tssK3, PA14∆tssK3ptssK3, PAO1, PAO1∆tssK3 and 
PAO1∆tssK3ptssK3 (Fig. 27). They all showed a similar growth pattern when they were 
cultured alone in ASM. Interestingly, TNCF_23 and TNCF_175, namely the strains isolated 
from CF patient, appeared to grow slightly faster than other strains. 
 
 
Figure 27. Growth of Pseudomonas aeruginosa in Artificial Sputum Medium. Single culture 
growth curves are represented. 
1568 bp 
1.5 kb 
kb 
2 kb 
 1      2     3      4      5     6      7      8     9     10    11    12    13   14 
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4.2.3.2. Bacterial competition in ASM 
To evaluate bacterial competition, isolates were subsequently co-cultured in pairs in ASM 
and studied at the same time-points as they were assessed when cultured alone. This 
implied diluting cultures in a 10-fold series and plating on selective agar plates to calculate 
the number of CFU. 
 
The first series of competitive ASM assays (Fig. 28) included: 
• TNCF_23 vs TNCF_175, in which TNCF_23 appeared to outcompete TNCF_175; 
• TNCF_175 vs VrPa97, in which VrPa97 dramatically outcompeted TNCF_175, 
leading the late chronic strain near to elimination; 
• TNCF_23 vs VrPa97, where instead the presence of another isolate in the culture 
didn’t affect growth compared to pure culture. 
 
Based on these results, to check for the presence of any secreted factors that could lead to 
bacterial toxicity, further analyses were performed. TNCF_175 growth in ASM was 
assessed in the presence of supernatants derived from: a) a TNCF_23 overnight culture; b) 
an overnight co-culture of TNCF_23 and TNCF_175; c) a VrPa97 overnight culture, and d) 
an overnight co-culture of VrPa97 and TNCF_175 (Fig. 29). No supernatant turned out to 
have any toxic effect on TNCF_175. These results suggested that growth inhibition 
observed in the competitive ASM assay is due to cell-cell interaction. 
 
To study a possible role of tssK3 impairment in this mechanism, a second series of 
competitive ASM assays (Fig. 30) was carried out; at this stage, six strain pairs were 
analysed: 
• VrPa97 vs PA14; 
• VrPa97 vs PA14∆tssK3; 
• VrPa97 vs PA14∆tssK3ptssK3; 
• VrPa97 vs PAO1; 
• VrPa97 vs PAO1∆tssK3; 
• VrPa97 vs PAO1∆tssK3ptssK3. 
 
In no cases VrPa97 significantly affected growth and survival of the other isolates. 
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Figure 28. ASM competition assay. In-pairs culture growth curves in ASM are represented. Clockwise, 
TNCF_23 vs. TNCF_175, TNCF_175 vs. VrPa97 and TNCF_23 vs. VrPa97. 
 
 
 
Figure 29. ASM assay performed on TNCF_175 in the presence of TNCF_23 and VrPa97 
cultures supernatants. 
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Figure 30. ASM competition assay. In-pairs culture growth curves in ASM are represented. In the left 
part of the panel, VrPa97 vs PA14, VrPa97 vs PA14∆tssK3 and VrPa97 vs PA14∆tssK3ptssK3 competitive 
growth in ASM is reported; in the right part of the panel, VrPa97 vs PAO1, VrPa97 vs PAO1∆tssK3 and 
VrPa97 vs PAO1∆tssK3ptssK3 competitive growth in ASM is represented. 
 
 
4.2.4. T6SS-mediated bacterial competition 
The type VI secretion system is a weapon that bacteria use to outcompete non-sister 
bacterial cells [154] by the direct injection of toxins. Based on data obtained with 
competitive ASM assays, an assay aimed at testing the functionality of T6SS was 
performed. The assay involves the E. coli strain MH5α as a target of the T6SS machinery 
[192]. 
Plates were checked after an overnight incubation by a qualitative evaluation based on the 
observation of colour intensity of blue colonies (E.coli DH5α); the more blue are the 
colonies, the less active Pseudomonas aeruginosa strain T6SS is. The highest intensity of 
blue spots was observed for TNCF_175, followed by the negative control PAK∆ret∆H1-
T6SS. TNCF_23 and the positive control PAK∆ret showed a similar pattern in the 
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distribution of blue shades in the spots. VrPa97, PA14, PA14∆tssK3, PA14∆tssK3ptssK3, 
PAO1, PAO1∆tssK3 and PAO1∆tssK3ptssK3 showed no blue shades in the qualitative 
analysis.  
A quantitative analysis was performed using the same assay, by plating 100 µl of the mixed 
cultures in a Petri dish and counting blue colonies. Results are reported in figure 31: 
TNCF_175 appeared to be the least aggressive against DH5α, even less than the negative 
control PAK∆ret∆H1-T6SS (with inactive T6SS), while its clonally related strain TNCF_23 
and genotypically related VrPa97 seemed to have a very active T6SS, more than PAK∆ret 
(positive control). PA14, PA14∆tssK3 and PA14∆tssK3ptssK3 appeared as the most 
aggressive towards DH5α, although differences could be observed within the three strains: 
a trend in decreasing DH5α killing could be spotted in PA14∆tssK3 compared with PA14. 
PA14∆tssK3ptssK3 seemed to gain back the original killing ability. However, no 
statistically significant difference could be calculated between these three isolates. PAO1 
and its relative mutants (PAO1∆tssK3 and PAO1∆tssK3ptssK3) showed a similar trend:  
PAO1∆tssK3 showed a slightly weaker killing activity compared to PAO1 and trend as 
PAO1∆tssK3ptssK3, although a statistical significance difference was found only between 
PAO1∆tssK3 and PAO1∆tssK3ptssK3, and not between PAO1 and PAO1∆tssK3 (unpaired 
t-test with Welch’s correction and Mann-Whitney test were applied). 
 
 
Figure 31. Quantitative analysis of T6SS-mediated DH5α killing by Pseudomonas aeruginosa 
isolates. Number of colonies of DH5α in the presence of bacterial strains are represented. 
 
4.2.5. Slow killing assay in Caenorhabditis elegans 
Caenorhabditis elegans has been used for numerous studies as an infection host for P. 
aeruginosa and many other bacteria [204]. To verify a possible role of T6SS, and 
particularly of tssK3, a slow killing assay was performed. TNCF_23 and VrPa97 showed a 
marked virulence against C. elegans (Fig. 32): Both strains provoked the death of all 
worms within six days.  TNCF_175 showed a mild virulence: all 50 C. elegans individuals 
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died after 15 days. Mantel-Cox test showed that curves representing survival rates of C. 
elegans in the presence of TNCF_23 and VrPa97 were not significantly different (P-value 
0.6619), whereas C. elegans survival rate in the presence of TNCF_175 was remarkably 
different from both TNCF_23 curve (P-value 0.0006) and VrPa97 curve (P-value 0.0004). 
All curves strikingly differed from C. elegans survival rate with OP50 (P-value <0.0001 
with VrPa97 and TNCF_23, and 0.0010 with TNCF_175). 
PA14, PA14∆tssK3 and PA14∆tssK3ptssK3 show a remarkably high killing activity in C. 
elegans (Fig. 33). Death of all 50 worms occurred within 7 days with both PA14 and 
PA14∆tssK3, and within 8 days with PA14∆tssK3ptssK3. Comparison of the three survival 
curves did not show any relevant differences. The same curves were all significantly 
different from OP50 curve: P-value <0.0001 in all three cases. 
PAO1 and PAO1∆tssK3 showed a comparable pattern in the killing of C. elegans: in both 
cases, all worms died within 18 days. PAO1∆tssK3ptssK3 appears to be slightly more 
virulent than the other two, with a total killing of worms occurring after 13 days, although 
survival rates were not significantly different between PAO1 and PAO1∆tssK3ptssK3, and 
between PAO1∆tssK3 and PAO1∆tssK3ptssK3 (P-value 0.8341 and 0.2118 respectively). 
Only the survival curve obtained with PAO1∆tssK3ptssK3 appeared to be significantly 
different from the curve obtained with OP50, with a P value of 0.0153 (Fig. 34). 
 
 
Figure 32. Survival rate of C. elegans in the presence of TNCF_23, TNCF_175 and VrPa97. 
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Figure 33. Survival rate of C. elegans in presence of PA14, PA14∆tssK3 and 
PA14∆tssK3ptssK3. 
 
 
 
 
 
Figure 34. Survival rate of C.elegans in the presence of PAO1, PAO1∆tssK3 and 
PAO1∆tssK3ptssK3. 
Each curve represents survival rate of C.elegans with respect to bacterial strain given. 
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4.2.6. Virulence in Galleria mellonella 
The greater wax moth caterpillar, Galleria mellonella, has been used in several studies as a 
useful model for investigating the pathogenesis of many bacterial and fungal pathogens 
[205][206][207]. The larvae were injected, on three different occasions, with a range of 
inoculum doses to determine the mortality rates caused by each isolate. VrPa97 strain was 
found to be significantly more virulent towards G. mellonella than TNCF_23 and 
TNCF_175 strains. Curve comparison showed significant differences (p<0.0001) for each 
strain, although the survival outcome of the tested strains varied. VrPa97 strain showed 
the highest virulence, causing higher mortality rates, compared to TNCF_23 and 
TNCF_175, and killed all the larvae already at a lower dose (102 CFU) after 24h-incubation. 
The killing rate exhibited by both TNCF_23 and TNCF_175 strains was positively 
correlated with both incubation time and dose. However, TNCF_175 strain was more 
virulent compared to TNCF_23 (Figs. 35-37). Non-infected larvae showed no mortality. 
 
 
Figure 35. Survival curves of Galleria mellonella larvae following injection of different doses 
of P. aeruginosa TNCF_23. Data presented are the mean + SD of three independent assays (n=30 
larvae/assay) with TNCF_23. PBS-injected larvae were used as controls and showed no mortality. 
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Figure 36. Survival curves of Galleria mellonella larvae following injection of different 
concentrations of P. aeruginosa TNCF_175.  Data presented are the mean + SD of three independent 
assays (n=30 larvae/assay) with TNCF_175. 
 
 
 
 
Figure 37. Survival curves of Galleria mellonella larvae following injection of different 
concentrations of P. aeruginosa VrPa97. Data presented are the mean + SD of three independent 
assays (n=30 larvae/assay) with VrPa97. 
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5. DISCUSSION 
Pseudomonas aeruginosa undergoes a characteristic evolutionary adaptation during 
chronic infection of CF lung [38]. Infection of CF patients occurs via primary colonization 
of the airway with subsequent accumulation of adaptive mutations in the bacterial genome 
related to an increased fitness in the lung environment, resulting in chronicization [23]. 
Adaptation to the airway of P. aeruginosa is a crucial aspect in the progression of CF lung 
disease and P. aeruginosa chronic isolates are known to express different phenotypic traits 
compared to acute infection isolates, including biofilm formation, loss of motility, and 
hypermutability [208][209][210][72]. Genomic studies have revealed extensive strain 
genetic variability within patients [38], and selection within CF lung appears to play a key 
role for P. aeruginosa diversification [38]. 
 
Population structure and microevolution. We obtained genome sequences from 40 
P. aeruginosa isolates from a single CF patient collected over an eight-year period (2007-
2014). Interestingly, Eburst analysis of the sequence types revealed that the collection 
consisted of a single clonal population dominated by ST390 plus three novel variants, with 
variations only at a single locus each, indicating that all isolates belonged to the same 
clonal lineage and likely evolved from a single ancestral colonizing strain. This is in 
contrast with what has been previously reported in other CF patients, in which either 
different lineages coexist [211][212][180] or a first infecting lineage is replaced by a new 
one [213][214]. In this patient, a single dominant clonal lineage apparently persisted in the 
airways for at least eight years, allowing a detailed study of the microevolution and 
adaptive process of the bacterium in the course of chronic infection. However, within this 
population, we could observe the presence of two sublineages that have evolved in parallel, 
with one of them being the most prevalent in the latest stage of the infection; not 
surprisingly, this sublineage comprised most multi-drug resistant isolates. In a 
retrospective analysis of serial isolate collections from CF patients starting at the onset of 
airways colonization over a 30-year period from 51 CF centres in Hannover and 
Copenhagen, Cramer et al. [215] provided a unique opportunity to understand the 
molecular evolution of P. aeruginosa in the course of chronic infection. Genotyping 
revealed that the P. aeruginosa population was dominated by a few ubiquitous clones. On 
the other hand, these authors also noticed a site-specific expansion of clones. Similarly to 
our findings, In Hannover, the clonal distribution resembled the global distribution in CF 
airways, namely the majority of the cohort maintained the initially acquired clone 
throughout the entire period of observation. However, in Copenhagen, two clones had 
replaced the initially acquired individual clones in the majority of cases. Since these two 
clones were rare in the global P. aeruginosa population, they had likely spread by 
nosocomial superinfection. 
Our phylogenetic analysis based on SNPs in the core genome also divided the population 
into two subpopulations derived from the evolution of the first infecting strain. The 
annotation of SNPs allowed us to identify mutations with moderate or high impact. The 
gene encoding respiratory nitrate reductase subunit gamma nail carried high impact 
variants in three closely related isolates, one early isolate, TNCF_14, and two late isolates, 
TNCF_130 and TNCF_151. Isolates TNCF_133 and TNCF_167_1 had high impact variants 
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in two genes encoding a polyprotein signal peptidase lspA and a hypothetical protein, and 
two hypothetical proteins, respectively. Other genes with high-impact variants were those 
encoding the ABC transporter-binding protein aaltP in TNCF_3, the copper resistance 
protein A precursor pcoAin TNCF_175 and a gene with unknown function in TNCF_174. 
With regard to moderate impact mutations, eight of them were found in genes with a 
putative or unknown function. The pyoverdine biosynthesis gene pvdL carried a total of 
five moderate-impact SNPs in all 40 genomes analysed, as well as the DNA gyrase subunit 
B gyrB with five variants in 36 genomes. Remarkably two aminoacid substitutions, E468-
D and S749-P, were found in isolates resistant to fluoroquinolones. The topoisomerase IV 
subunit B parE gene showed three different variations within the population, including 
R30-C and H59-R in the late MDR isolates. The two-component regulatory system signal 
sensor kinase pmrB gene showed three different changes among the population; glnE and 
rsme (yggJ) carried three different variants, while cbrA and gltB, nagE, aruF and pilL had 
three moderate variants in five, four and three different genomes, respectively. 
Molecular evolution analysis was performed to identify genes under non-neutral selective 
pressure. We found that at least three genes, gyrB, parE and pmrB, involved in the 
resistance to different classes of antibiotics carried mutations potentially affecting protein 
function. In particular, DNA gyrase gyrB and topoisomerase IV parE are both major 
contributors to the acquisition of resistance to fluoroquinolones [34]. Clinical isolates with 
the aminoacid substitution E468-D in GyrB protein is reported to be associated to a high-
level of resistance to ciprofloxacin [34][212], as this variation is within the quinolone 
resistance-determining regions (QRDRs) of the protein, whereas the mutations found in 
parE are outside the QRDR domain. For both genes, according to the likelihood ratio test, 
the null hypothesis of neutrality was rejected. Therefore, non-neutral selection is acting on 
those genes in the population. Sensor kinase PmrB is part of the two-component 
regulatory system PmrA/PmrB involved in resistance to Polymyxins and other cationic 
antimicrobial peptides in P. aeruginosa CF isolates [216][217][218]. Considering that 
variations found in this population were not directly associated with an MDR phenotype 
and that this gene was not found to have non-neutral selective pressure (likelihood ratio 
test > 0.05), we can assume that the mutations are neutral. 
Mutations in virulence genes, like pyoverdine biosynthesis gene pvdL and pilin 
biosynthesis gene chpA (pilL), are known as hallmarks of adaptation of P. aeruginosa 
strains to the CF airway environment [219]. Siderophore-mediated processes have been 
linked with virulence regulation of P. aeruginosa and its pathogenic potential [38]. 
However, in a study conducted on 36 CF patients, pyoverdine was undetectable in one-
third of sputa positive for P. aeruginosa [220]. The presence of pili is necessary for the 
initial colonisation and the translocation of type III exotoxins [221], but adapted and late 
CF isolates accumulate mutations in genes associated with pili, and loss of motility is 
associated with a higher risk of persistent infections [213][222]. 
Among the 20 most variable genes (with at least three variations within the population) 
selected for the analysis of adaptive evolution, nine resulted to be under non-neutral 
pressure (namely gyrB and parE, pilL, nagE, gltB, gidA and three genes encoding 
hypothetical proteins). For 10 of them, the neutral (null) hypothesis could not be rejected. 
For one gene, pvdL, it was not possible to perform the test, because its sequence was 
incomplete, probably due to the draft nature of the genomes. All genes for which the 
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likelihood ratio test rejected the null hypothesis had an omega (dN/dS) > 1, suggesting 
they are under positive selection.  
We compared the list of genes most frequently mutated in the international strain 
collection analysed by Greipel et al. [223] (spuE, spuF, mexA, oprM, rpoB, fusA1, gyrA, 
mexS, fusA2, mexZ, mexY, parR, parS, oprD, ampD, pagL, amgS), with the one obtained 
in our study: we could not find an exact correspondence between the two lists. However, 
the frequency of sequence variants in our population is higher in genes related or 
belonging to the same functional category than the ones present in the Greipel study. We 
found indeed the highest number of variants in the following genes: gyrB and parE 
directly related to gyrA and parR/parS respectively; furthermore, we found a frameshift 
mutation in oprD (∆C437), present in Greipel’s study too, and amino acid variations in the 
efflux pump mexG and the topoisomerase parC. In addition, we found a high number of 
variations in the pyoverdine biosynthesis gene pvdl, known to play a role in the adaptive 
process, and in the sensor kinase pmrB, involved in the production of cationic 
antimicrobial peptides and polymyxin resistance. 
Six genomic islands were found in all genomes of the population, three of them were not 
identified, whereas the other three were tentatively assigned to LESGI-1, PAGI-2 and 
LESGI-3. LESGI-1 and LESGI-3 were first identified and characterised in the epidemic P. 
aeruginosa strain LESB58 [184].  LESGI-1 is described to contain phage- and transposon-
related genes, together with coding sequences showing similarity with proteins of non-
pseudomonad species [184]. LESGI-3 island has a mosaic compositional structure and 
present a significant homology to PAGI-2, PAGI-3, PAGI-5, and PAPI-1 [184][224] and, up 
to now, it was described to be an island unique to the LESB58 strain, since its particular 
structure was not found in other strains [225][226]. However, even if three protein clusters 
showed high identity with both LESGI-3 and PAGI-2, we saw two further protein clusters 
with an exclusive assignment to LESGI-3 in a different genomic region. We, therefore, 
consider more parsimonious to assign the first genomic region to PAGI-2 and the second 
genomic region, located about 1Mb downstream, to LESGI-3, rather than speculating on 
an event of duplication of LESGI-3. PAGI-2 was initially described in P. aeruginosa clone 
C isolates [227]. This island is divided into two main phage modules, one coding for 
chromosome-partitioning proteins (soj) and another containing a bacteriophage P4-
related integrase [50]. PAGI-2 is present in approximately 40 % of P. aeruginosa strains 
[228]. 
The evolution of strains in the CF airway is characterized by the loss of many virulence 
traits, including motility and protease secretion, along with the acquisition of multidrug 
resistance [23]. Functional phenotypic assays of the collection, including motility and 
secretion of proteases, showed a general decrease of these traits over time in the persistent 
isolates. In some cases, as previously reported [40][45], we observed the contemporary 
presence of isolates retaining traits typical of an early stage of infection (motility and 
secretion of proteases) and of isolates showing the typical characteristics of adaptation 
(loss of virulence factors, increased antibiotic resistance, overproduction of alginate and 
biofilm formation). Spearman’s correlation analysis showed a decrease in alginate 
production over time. Mucoid phenotype was present mainly in earlier and intermediate 
isolates; previous studies have reported that P. aeruginosa loses mucoid phenotypes in the 
latest stages of CF lung disease, because its production requires high levels of energy 
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[18][57]; however, this is in contrast with what has been traditionally observed for the 
mucoid phenotype, that is associated with late stages of infection. Furthermore, in our 
work we observed that the same mucoid strain did not always show the exact amount of 
mucus when cultured on agar plates at different times; this may suggest that environment 
plays an important role on mucoidy, and that in vitro observations might significantly 
differ from what occurs in vivo, as described by Bragonzi et al. [229]. 
Swarming motility and protease production were present only in the earliest isolates. Lack 
of motility is usually associated with decreased virulence [230]. No isolate in our 
population showed twitching motility, which has been studied as an essential trait, along 
with mucoidy, to best predict subsequent pulmonary exacerbation [186]. The appearance 
of these phenotypes can be used as a potential marker of transition to chronic infection 
and advanced lung disease [186]. In previous studies [231][232] protease production was 
documented to change throughout infection, decreasing significantly in late chronic 
isolates, and this situation reflects our results, where we could only find protease secretion 
in a few early isolates. Biofilm formation assay showed that our isolates grew as sessile 
community mainly in the intermediate-late stage of infection. Biofilms are clinically 
relevant: biofilm-mediated infections that occur on medical devices like intravascular and 
urinary catheters, orthopaedic devices, and dialysis machines [233][234]. Chronic 
infections, such as recurrent ear infections and lung infections in CF patients, are caused 
by biofilm-dwelling bacteria [235][236][237]. Biofilms are known to be involved in 65–
80% of all bacterial infections [238][234]. Also, biofilm growth offers a competitive 
advantage with respect to planktonic growth [239]: bacteria in biofilms are difficult to 
disrupt, and biofilms are often associated with antimicrobial resistance [234]. A positive 
correlation with the time of isolation was found for the hypermutable phenotype, which is 
a typical trait of P. aeruginosa chronic isolates [18]. Interestingly, all hypermutable strains 
were resistant to most of the antibiotics tested, with the only exception of TNCF_133_1 
that is MDR but not hypermutable. The correlation could be explained considering that 
defects in the mismatch repair system cause a higher rate of mutability that can lead to the 
accumulation of mutations which can confer antibiotic resistance, as well as an enhanced 
genetic adaptation to CF airway [180][240]. Marvig et al. [45] found that different 
evolutionary paths of hypermutators can occur; they found a linear correlation between the 
number of SNPs and the time of sampling. From their collection of 55 DK2 genomes, nine 
sublineages had accumulated mutations at higher rates than expected, likely due to 
mutations in mismatch repair and error prevention genes. In total, they found 11 
hypermutator strains within 55 isolates. In two patients, they found that hypermutator and 
normomutator clones coexisted, probably because different lineages lived in different 
niches within patients’ lungs. 
Overall MDR P. aeruginosa strains are developing with increasing frequency, leading to a 
triplication in their rates in the last two decades [241][242]. Some P. aeruginosa isolates 
have been found to be resistant to almost all or all antibiotics in clinical use [242], and 
estimates suggest that 25-45% of adult CF patients are chronically infected with MDR P. 
aeruginosa within their airways [243]. Antibiotic susceptibility profiles of the collection 
were determined for 12 molecules belonging to aminoglycosides, cephalosporines, 
fluoroquinolones, polymixins, β-lactams and carbapenems.  While early isolates were 
found to be susceptible to almost all these antibiotics, resistant phenotypes dramatically 
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increased over time in the population. Pseudomonas aeruginosa is considered a paradigm 
of antimicrobial resistance development. It is intrinsically resistant to several antibiotics 
because of the low permeability of its outer membrane, the constitutive expression of 
various efflux pumps, and the production of antibiotic-inactivating enzymes [65]. Besides 
intrinsic resistance mechanisms, P. aeruginosa develops resistance during persistence in 
the airways by the accumulation of pathoadaptive mutations in genes encoding antibiotic 
resistance [64], e.g. β-lactamases and efflux pumps [9]. Although many mutations 
contributing to drug resistance have been identified, the relationship between specific 
mutations and the related phenotypic changes leading to resistance has yet to be fully 
elucidated. Genome analysis helps to predict potential molecular mechanisms of resistance 
and to identify gene products involved in antibiotic transport and efflux from bacterial 
cells. Whole-genome sequencing (WGS) has already proved to be able to predict 
antimicrobial susceptibility in several pathogens [244][245][52]. 
All the isolates in our collection were sensitive to Colistin, whereas nearly all the early 
isolates were susceptible to almost all the antibiotics tested, while the population became 
multiresistant during the persistance in the airways. Colistin (or polymyxin E) has been 
available on the market since 1959, but its use declined because of nephrotoxicity and 
neurotoxicity [246][247][248]. With the emergence of multidrug-resistant pathogens (e.g. 
Acinetobacter baumannii, P. aeruginosa and carbapenem-resistant Enterobacteriaceae), 
physicians started to use it again [249], although it remains a last-resort treatment. 
Genomic analyses of the population showed a correlation between the evolution of 
antibiotic resistance profiles, MLST sequence types, and phylogenetic relationships. We 
further investigated the MDR isolates in comparison to the susceptible ones, looking 
specifically at the coding sequences of P. aeruginosa genes involved in antibiotic resistance 
and susceptibility. As described above, non-synonymous mutations were found in gyrB, 
parE and pmrB; additional variants present in the MDR isolates compared to the 
susceptible ones were: ∆C437 in the outer membrane porin gene oprD leading to a 
frameshift mutation in nearly all MDR isolates, P51-S in MexG and N170-S in the 
topoisomerase IV subunit A ParC. 
The outer membrane protein OprD is involved in the resistance against β-lactams and 
carbapenems [250].  The protein contains 16 β-strands connected by short loops, eight of 
wich are external loops [251]. The deletion present in the MDR strains of the population 
disrupts the protein just before the fourth loop, and it is reported that the deletion of loops 
3 and 4 results in a non-stable expression of the protein [251]. In P. aeruginosa repression 
or inactivation of OprD or a reduced protein expression contribute to moderate resistance 
to Imipenem [252] [253] [254], and carbapenem-resistant strains are often defective in 
expression of OprD [255]. Moreover, P. aeruginosa PA14 mutants for oprD showed an 
enhanced fitness in a murine model of mucosal colonisation and dissemination [256].  
MexG, a component of the efflux pump MexGHI-OpmD, carries an amino acid 
substitution, P51-S, in nearly all the MDR isolates; mutations in this pump are involved in 
the resistance to tetracycline and ticarcillin-clavulanate and implicated in the export of 
non-antibiotic compounds, including Vanadium [257]. 
Even if the N170-S substitutions present in ParC in the MDR isolates is outside the QRDR 
domain, mutations in the topoisomerase IV subunit A parC gene, along with those 
described above in gyrB and parC, confer resistance to fluoroquinolones [258] [259] and 
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clinical isolates with mutations in the QRDR of gyrA and parC show high levels of 
fluoroquinolone resistance [260]. Aminoacid substitutions variations in gyrB and parE 
genes have a low frequency in clinical isolates, and they are described to have only a 
complementary role in fluoroquinolone resistance [258] [260]. In a recent study [261], 
most of the P. aeruginosa clinical isolates analysed had mutations in gyrA or gyrB or both 
gyrA and parC. The latter confers a resistant phenotype, with only a few isolates exhibiting 
mutations in only in gyrB in combination with parE. Marvig et al. [45] reconstructed the 
evolutionary history of the DK2 lineage and identified bacterial genes targeted by 
mutations to improve pathogen fitness, and found that several pathoadaptive genes in 
which they found multiple mutations were associated with antibiotic resistance such as 
ampC (β-lactams), emrB (quinolones), ftsI (penicillins, chloramphenicol, tetracyclines), 
fusA (fusidic acid), gyrA/B (quinolones), mexB/Y (β-lactams, quinolones, 
aminoglycosides, tetracyclines), pmrB (polymyxins), pprA (aminoglycosides), oprD (β-
lactams), and rpoB/C (aminoglycosides, β-lactams, macrolides, tetracyclines).  
 
Functional studies on specific strains. Caenorhabditis elegans has been used for 
numerous studies as an infection host for Pseudomonas aeruginosa and many other 
bacteria [204]. When C. elegans is fed with P. aeruginosa PA14, the gut is colonized and 
death occurs within days, alternatively known as slow killing [262][263]. In contrast, the 
fast killing assay results in C. elegans death within hours. While the fast killing assay does 
not necessarily require live bacteria and is caused by the production of secreted toxins 
including phenazines [264], the slow killing requires ingestion of live bacteria and their 
virulence factors [263]. Pseudomonas aeruginosa strains display a wide range of virulence 
phenotypes, where PA14 is among the most virulent strains and PAO1 among the ones with 
moderate slow killing activity [265]. The virulence requirements may vary within P. 
aeruginosa isolates as PAO1 was shown to induce a rapid, paralytic killing mechanism 
dependent on hydrogen cyanide production [266].  Our data clearly indicated that the 
acute-infection strain and the early CF isolates have a significantly higher killing rate 
compared to the late-infection isolate. Several delivered toxins have been reported as 
necessary for P. aeruginosa for killing C. elegans [262]. In previous investigations, we had 
noticed that TNCF_23 (early CF strain) and VrPa97 (acute strain) produce pyoverdine, 
while TNCF_175 (late CF strain) does not. This is consistent with a previous study 
reporting how C. elegans is killed by pyoverdin which uptakes iron from intracellular 
compartments, therefore functioning as a toxin [267]. 
The greater wax moth caterpillar, Galleria mellonella, has been used in several studies as 
an effective model for investigating the pathogenesis of many bacterial and fungal 
pathogens [205][206][207]. Advantages of this model include the ability to incubate larvae 
over a range of temperatures (15-37°C), ease of maintenance and handling and that the 
bacteria or drug inoculum can be accurately quantified prior to infection [268][269][270]. 
In the experiments with Galleria mellonella, VrPa97 appeared to be very aggressive, while 
TNCF_175 was significantly less virulent compared to VrPa97. TNCF_23 was instead 
weakly aggressive against G. mellonella, unlike what happened in the C. elegans assay.  In 
a study of P. aeruginosa mutants, lipopolysaccharide-deficient isolates showed 
significantly reduced virulence in G. mellonella, whereas mutants with defects in pili, 
flagella, or proteases did not [271]. TNCF_23 is defective in type IV pili production, and 
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this may explain its reduced virulence against G. mellonella. The acute-infection strain 
VrPa97 is instead capable of killing both organisms. The late strain TNCF_175 showed low 
killing rates towards both G. mellonella and C. elegans, and this is consistent with a 
previous study that showed CF late chronic isolates to be less virulent compared to early-
infection isolates [272]. 
In our study, we have also determined that, with the progression of the infection, 
immunomodulatory properties of isolates vary. Specifically, in the late stage of the 
infection the ability to induce cytokine secretion diminishes, while in the acute infection 
and early CF infection interleukin production is abundant. This is in complete agreement 
with previous studies in which multiple P. aeruginosa virulence factors (such as pilin, 
flagellin, proteases) have been shown to increase secretion of the chemokine IL-8 by 
human airway epithelial cells [201][202][203]. Loss of flagella allows bacteria to evade the 
immune system, thanks to the loss of engagement by phagocytic receptors that recognize 
flagellar components, and to the loss of immune activation through flagellin-mediated TLR 
signalling [273]. Loss of P. aeruginosa motility radically alters immune responses, but not 
flagellum expression itself, that results in bacterial resistance to phagocytosis by 
phagocytes [273]. Similarly, studies in the agar beads murine model using P. aeruginosa 
isolates from patients with CF showed that the risk of chronic infection is increased by the 
absence of pili and flagella [41]. In addition, TNCF_175 appeared to internalize more than 
VrPa97 and TNCF_23 in A549 cells. Internalization could benefit bacterial survival 
through evasion of host phagocytic- and antibody/complement-mediated killing 
mechanisms. Furthermore, in CF, a decreased internalization of P .aeruginosa in CFTR 
deficient cells may increase bacterial burdens and contribute to establish chronic infection 
in the lung [200][274]. 
To better understand the adaptation of selected strains, we observed their growth in 
Artificial Sputum Medium (ASM). ASM is a culture medium containing amino acids, 
mucin and free DNA, that mimics the composition of CF patient sputum. Pseudomonas 
aeruginosa growth in ASM should thus reflects growth during CF infection, with the 
formation of self-aggregating biofilm structures and population divergence 
[275][276][277]. ASM was originally created to study biofilm formation; in particular, it 
was noticed that P. aeruginosa grows as microcolonies in an environment that resembles 
CF lungs. This particular biofilm does not attach to the surface, whereas bacteria adhere to 
each other in the centre of the well [275]. Previous studies have used ASM models to study, 
for example, gene expression patterns and the effects of bacteriophages on P. aeruginosa 
[278][279][275]. Our results showed a general higher fitness of CF isolates in ASM 
compared with acute-infection strains or reference laboratory strains. In the competitive 
assay in ASM, the late isolate (TNCF_175) grew more slowly compared to the other two 
isolates, either when it was cultured alone or in pairs with VrPa97 or TNCF_23, suggesting 
the occurrence of a cell-to-cell interaction by which VrPa97 can kill FC175.  
At this stage, we hypothesized that TNCF_175 was altered in one or more of its contact-
dependent delivery systems. This hypothesis was corroborated by the finding of a mutation 
in TNCF_175 tssK3 gene that could be associated with its lack of competitive growth 
ability. The mutation (C958T) leads to a premature stop-codon. The gene encodes a not yet 
characterized protein that is likely to be part of the baseplate in H3-T6SS. T6SS is the main 
contact-dependent delivery system responsible for the interactions between bacterial cells. 
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Several Gram-negative bacteria show at least one type of T6SS. Pseudomonas aeruginosa 
has three different T6SSs, recently found to be interdependent [137]: H1-, H2- and H3-
T6SS. The extensively characterized H1-T6SS is known to be active against prokaryotic 
cells [116], while H2- and H3- have been shown to be active against either prokaryotic and 
eukaryotic cells [136][134]. T6SSs consist of effectors (proteins intended to attack 
neighbour cells by injecting toxins) and immunity proteins (proteins that protect the cells 
by attacks from T6SS of other cells) [116][128][127]. 
When testing T6SS functionality, we observed that TNCF_175 had an impaired T6SS, 
while that of TNCF_23 and VrPa97 was functional. The tssK3-encoded protein has 
currently not been characterized. Previous studies have demonstrated that its H1-T6SS 
homologous protein TssK is a trimer and is an essential subunit of the type VI secretion 
apparatus by connecting the trans-envelope membrane-complex to the phage-like 
contractile tail [157]. In addition, TssK has been shown to be part of the T6SS assembly 
platform or baseplate [280][150][152][281][157]. The same tssK3 mutation has been found 
in other eight isolates from our collection: interestingly, the five latest isolates all carry the 
mutation, which appeared for the first time in TNCF_105, isolated in 2011. All tssK3-
mutated strains belong to the MDR cluster of our phylogenetic analysis. In fact, the 
mutation seems to be conserved, suggesting that the disruption of the baseplate, and 
therefore of the H3-T6SS syringe, might have occurred because once the isolates have 
established in their niche in CF lung, no more warfare against other bacteria is required. 
Our results showed that bacterial cell-cell contact damages TNCF_175, and at the same 
time TNCF_175 cannot out-compete other strains, suggesting that TNCF_175 has both 
effector and immunity T6SS compartments impaired. Therefore, different mechanisms, 
along with the disruption of the H3-T6SS baseplate, are likely to contribute to the dramatic 
impairment of the whole attack/defense machinery in the late isolate TNCF_175.  
To better understand the role of tssK3 in the observed phenotypes, clean deletion mutants 
for this gene in the background of reference strains PA14 and PAO1 were constructed, 
PA14∆tssK3 and PAO1∆tssK3. Clean mutants were subsequently complemented with a 
plasmid containing a constitutively expressed tssK3 (PA14∆tssK3ptssK3 and 
PAO1∆tssK3ptssK3). No significative differences were spotted in the growth rate in ASM of 
each strain co-cultured with VrPa97, suggesting that the tssK3 impairment itself is not 
sufficient to explain TNCF_175 inability to survive in presence of VrPa97. These results 
suggest that tssK3 may not be involved in T6SS-mediated immunity. Additional data were 
obtained by a series of E. coli DH5α killing assay performed with PA14, PA14∆tssK3, 
PA14∆tssK3ptssK3, PAO1, PAO1∆tssK3 and PAO1∆tssK3ptssK3. Although data could not 
be statistically validated in all cases, a clear trend could be observed: both mutants, 
PA14∆tssK3 and PAO1∆tssK3 showed a reduced capability to kill E. coli compared to the 
relative wild-type and complemented strains. This would suggest that TssK3 is likely to 
play an important role in the correct functioning of H3-T6SS, allowing P. aeruginosa to 
attack neighbour cells, as previously demonstrated for TssK in H1-T6SS [159]. To 
investigate a possible role of tssK3 in virulence against eukaryotic organisms as a support 
in toxin injection, PA14, PA14∆tssK3, PA14∆tssK3ptssK3, PAO1, PAO1∆tssK3 and 
PAO1∆tssK3ptssK3 were assessed for their capability of killing C. elegans. PA14, 
PA14∆tssK3 and PA14∆tssK3ptssK3 showed a remarkably high killing activity in C. 
elegans, with no significant difference among the three strains. PA14 is naturally very 
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aggressive against eukaryotes. Therefore it is difficult in this case to evaluate the role of 
tssK3 in C. elegans killing, because of the presence of other virulence factors that may play 
a role. PA14 is well known to slowly kill C.elegans by accumulating and ejecting toxins in 
the intestinal lumen of the worm [262]. The same study showed that among 10 PA14 
mutants, with different altered virulence-related genes, six of them showed a slightly 
decreased killing activity, while four of them showed the same aggressive behaviour 
against C. elegans as PA14 wild-type, suggesting that the combination of several factors is 
required for pathogenicity. PAO1 and PAO1∆tssK3 showed a very mild killing activity, 
while PAO1∆tssK3ptssK3 appeared to be noticeably more aggressive against C. elegans. 
This is probably because in the complemented strain tssK3 is constitutively expressed, and 
it can thus contribute making the strain more virulent by maintaing the H3-T6SS 
constantly active. In PAO1 instead, tssK3 is under the control of its native promoter that 
appears to be inactive in this context. It has been previously shown that PAO1 is not 
harmful for C. elegans when it is grown on Nematode Growth Medium, but it is toxic for C. 
elegans when it is grown on rich brain–heart infusion medium, by a mechanism that 
involves the generation of one or more neurotoxins, including hydrogen cyanide 
[282][266]. 
To sum up, our results contribute to demonstrate that chronic-infection strains in CF 
appear to be phenotypically “weaker” compared to the early infection strains, but at the 
same time they are able to persist and survive in the lungs for a long time. This is an 
important aspect, since persistence in the lung relies on a finely drawn up 
pathoadaptation, consisting in the accumulation of a set of loss-of-function mutations that 
allows bacteria to establish permanently in lung niches.  
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6. CONCLUSION AND PERSPECTIVES 
A rare feature of our strain collection is the consistent number of clonal isolates obtained 
from a single patient over a period of 8 years, thus providing a model to look at 
microevolutionary trends within a highly homogenous bacterial population, and avoiding 
potential biases due to the host genetic background and clinical history. In spite of the 
close genomic relatedness of all isolates, a surprisingly high diversity was observed for 
most tested phenotypes, with particular reference to antibiotic susceptibility profiles. We 
observed an increased frequency of MDR isolates in the course of time in CF infection, 
which could not be explained by variations in known resistance genes. Uncharacterised 
variations revealed in this study should be further investigated to increase our knowledge 
on the emergence of MDR phenotypes. 
 By investigating the competitive ability of early versus late strains, we propose a role for 
T6SS in the adaptation process to the CF lung environment. Our data suggest that once 
persistence has been established, a strain no longer requires its T6SS, in which loss of 
function mutations may occur. Conversely, acute and early CF strains still carry a number 
of virulence factors, including T6SS that might provide an advantage in outcompeting 
other microorganisms in the initial stage of CF infection. Further studies are required to 
better understand the role of T6SS component TssK3. A secretion assay of Hcp3 protein to 
assess the effective activity of the H3-T6SS should be performed. Following the same 
approach as Ngyuyen et al. with the homologous TssK [159], it would be extremely useful 
to get a cristal of the protein to get insights into structural aspects. Transcriptomic 
approaches would also be helpful to better understand how the expression of genes 
encoding H3-T6SS units runs in the isolates belonging to our collection. It would also be 
useful, to verify the T3SS/T6SS switch and the underlying adaptation processes, to analyse 
the c-di-GMP levels in these strains. We have already obtained tssK3 mutants in the 
background of reference strains PAO1 and PA14 that can be used for further analyses. 
However, to assess the role of the gene in clinical strains from our collection, it would be 
ideal to obtain mutant in the background of one of these strains. In spite of many attempts 
to mutate TNCF_23 during this study, no transformation was possible neither using 
electroporation nor conjugation, a known fact for CF strains that could be attributed to the 
large amount of exopolysaccharides surrounding cells, thus impeding transformation. 
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